

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Emerging therapies against infections with... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1371/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1371" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Emerging therapies against infections with Pseudomonas aeruginosa" />
    
            <meta name="og:title" content="F1000Research Article: Emerging therapies against infections with &lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt;.">
            <meta name="og:description" content="Read the latest article version by Burkhard T&uuml;mmler, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="21389">
            <meta name="article-id" content="19509">
            <meta name="dc.title" content="Emerging therapies against infections with &lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt;">
            <meta name="dc.description" content="Infections with Pseudomonas aeruginosa have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and societal impact. P. aeruginosa is one of the six ESKAPE pathogens that are the major cause of nosocomial infections and are a global threat because of their capacity to become increasingly resistant to all available antibiotics. This review reports on current pre-clinical and clinical advances of anti-pseudomonal therapies in the fields of drug development, antimicrobial chemotherapy, vaccines, phage therapy, non-bactericidal pathoblockers, outer membrane sensitizers, and host defense reinforcement.">
            <meta name="dc.subject" content="Pseudomonas aeruginosa, antibiotic, &szlig;-lactam inhibitor, vaccine, phage therapy ">
            <meta name="dc.creator" content="T&uuml;mmler, Burkhard">
            <meta name="dc.date" content="2019/08/07">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.19509.1">
            <meta name="dc.source" content="F1000Research 2019 8:1371">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Pseudomonas aeruginosa">
            <meta name="prism.keyword" content="antibiotic">
            <meta name="prism.keyword" content="&szlig;-lactam inhibitor">
            <meta name="prism.keyword" content="vaccine">
            <meta name="prism.keyword" content="phage therapy ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/08/07">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1371">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.19509.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1371">
            <meta name="citation_title" content="Emerging therapies against infections with &lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt;">
            <meta name="citation_abstract" content="Infections with Pseudomonas aeruginosa have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and societal impact. P. aeruginosa is one of the six ESKAPE pathogens that are the major cause of nosocomial infections and are a global threat because of their capacity to become increasingly resistant to all available antibiotics. This review reports on current pre-clinical and clinical advances of anti-pseudomonal therapies in the fields of drug development, antimicrobial chemotherapy, vaccines, phage therapy, non-bactericidal pathoblockers, outer membrane sensitizers, and host defense reinforcement.">
            <meta name="citation_description" content="Infections with Pseudomonas aeruginosa have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and societal impact. P. aeruginosa is one of the six ESKAPE pathogens that are the major cause of nosocomial infections and are a global threat because of their capacity to become increasingly resistant to all available antibiotics. This review reports on current pre-clinical and clinical advances of anti-pseudomonal therapies in the fields of drug development, antimicrobial chemotherapy, vaccines, phage therapy, non-bactericidal pathoblockers, outer membrane sensitizers, and host defense reinforcement.">
            <meta name="citation_keywords" content="Pseudomonas aeruginosa, antibiotic, &szlig;-lactam inhibitor, vaccine, phage therapy ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Burkhard T&uuml;mmler">
            <meta name="citation_author_institution" content="Clinical Research Group &lsquo;Molecular Pathology of Cystic Fibrosis&rsquo; and &lsquo;Pseudomonas Genomics&rsquo;, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, 30625, Germany">
            <meta name="citation_author_institution" content="Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), German Center of Lung Disease, Hannover, 30625, Germany">
            <meta name="citation_author_institution" content="Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, 30625, Germany">
            <meta name="citation_publication_date" content="2019/08/07">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1371">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.19509.1">
            <meta name="citation_firstpage" content="1371">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1371/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1371.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=21389 /> <input type=hidden id=articleId name=articleId value=19509 /> <input type=hidden id=xmlUrl value="/articles/8-1371/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1371-v1.xml"> <input type=hidden id=article_uuid value=0eff2244-23d3-4064-8840-1f3d64839ba8 /> <input type=hidden id=referer value=""/> <input type="hidden" id="meta-article-title" value="Emerging therapies against infections with <i>Pseudomonas aeruginosa</i>" /> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.19509.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.19509.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1371"
  },
  "headline": "Emerging therapies against infections with Pseudomonas aeruginosa",
  "datePublished": "2019-08-07T13:57:05",
  "dateModified": "2019-08-07T13:57:05",
  "author": [
    {
      "@type": "Person",
      "name": "Burkhard T&uuml;mmler"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Infections with Pseudomonas aeruginosa have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and societal impact. P. aeruginosa is one of the six ESKAPE pathogens that are the major cause of nosocomial infections and are a global threat because of their capacity to become increasingly resistant to all available antibiotics. This review reports on current pre-clinical and clinical advances of anti-pseudomonal therapies in the fields of drug development, antimicrobial chemotherapy, vaccines, phage therapy, non-bactericidal pathoblockers, outer membrane sensitizers, and host defense reinforcement."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1371/v1",
            "name": "Emerging therapies against infections with Pseudomonas aeruginosa"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Emerging therapies against infections with Pseudomonas aeruginosa </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=21389 data-id=19509 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19509.1" data-recommended="" data-doi="10.12688/f1000research.19509.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1371/v1/pdf?article_uuid=0eff2244-23d3-4064-8840-1f3d64839ba8" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-19509-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-19509-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-19509-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Tümmler B. Emerging therapies against infections with <i>Pseudomonas aeruginosa</i> [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1371 (<a class=new-orange href="https://doi.org/10.12688/f1000research.19509.1" target=_blank>https://doi.org/10.12688/f1000research.19509.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-19509-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=19509 id=track-article-signin-19509 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19509?target=/articles/8-1371/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21389 /> <input name=articleId type=hidden value=19509 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Emerging therapies against infections with <i>Pseudomonas aeruginosa</i></h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:tuemmler.burkhard@mh-hannover.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Burkhard T&uuml;mmler</span></a><a href="https://orcid.org/0000-0002-2566-8758" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2566-8758</div><sup>1-3</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:tuemmler.burkhard@mh-hannover.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Burkhard T&uuml;mmler</span></a><a href="http://orcid.org/0000-0002-2566-8758" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2566-8758</div><sup>1-3</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 07 Aug 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.19509.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Clinical Research Group &lsquo;Molecular Pathology of Cystic Fibrosis&rsquo; and &lsquo;Pseudomonas Genomics&rsquo;, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, 30625, Germany<br/> <sup>2</sup> Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), German Center of Lung Disease, Hannover, 30625, Germany<br/> <sup>3</sup> Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, 30625, Germany<br/> <p> <div class=margin-bottom> Burkhard T&uuml;mmler <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=53298-52186></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=53299-52187></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Infections with <i>Pseudomonas aeruginosa </i>have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and societal impact. <i>P. aeruginosa </i>is one of the six ESKAPE pathogens that are the major cause of nosocomial infections and are a global threat because of their capacity to become increasingly resistant to all available antibiotics. This review reports on current pre-clinical and clinical advances of anti-pseudomonal therapies in the fields of drug development, antimicrobial chemotherapy, vaccines, phage therapy, non-bactericidal pathoblockers, outer membrane sensitizers, and host defense reinforcement. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Pseudomonas aeruginosa, antibiotic, ß-lactam inhibitor, vaccine, phage therapy </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Burkhard T&uuml;mmler (<a href="mailto:tuemmler.burkhard@mh-hannover.de">tuemmler.burkhard@mh-hannover.de</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Burkhard Tümmler </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> Work in the author’s laboratory is supported by the Deutsche Forschungsgemeinschaft (DFG) (Collaborative Research Centre 900, projects A2 and Z1, grant 158989968; Germany’s Excellence Strategy – EXC 2155 “RESIST” – project ID 39087428) and the Bundesministerium für Bildung und Forschung (BMBF) (German Center for Lung Research, Disease Area Cystic Fibrosis at BREATH, grant 82DZL002A1). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Tümmler B. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Tümmler B. Emerging therapies against infections with <i>Pseudomonas aeruginosa</i> [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1371 (<a href="https://doi.org/10.12688/f1000research.19509.1" target=_blank>https://doi.org/10.12688/f1000research.19509.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 07 Aug 2019, <b>8</b>(F1000 Faculty Rev):1371 (<a href="https://doi.org/10.12688/f1000research.19509.1" target=_blank>https://doi.org/10.12688/f1000research.19509.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 07 Aug 2019, <b>8</b>(F1000 Faculty Rev):1371 (<a href="https://doi.org/10.12688/f1000research.19509.1" target=_blank>https://doi.org/10.12688/f1000research.19509.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><p class="" id=d20924e166>In humans, the aquatic gamma-proteobacterium <i>Pseudomonas aeruginosa</i> may cause multiple infections that vary from local to systemic and from benign to life-threatening. The management of the severe ocular<sup><a href="#ref-1">1</a></sup> and burn<sup><a href="#ref-2">2</a></sup> infections has made substantial progress during the last 20 years, but pneumonia and sepsis, particularly of ventilated patients in intensive care units (ICUs), are still burdened with high morbidity and lethality<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a></sup>. Chronic airway infections with <i>P. aeruginosa</i> are a major co-morbidity in patients with cystic fibrosis (CF)<sup><a href="#ref-5">5</a></sup>, bronchiectasis<sup><a href="#ref-6">6</a></sup>, or chronic obstructive pulmonary disease (COPD)<sup><a href="#ref-7">7</a></sup>.</p><p class="" id=d20924e203>Infections with <i>P. aeruginosa</i> have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and societal impact<sup><a href="#ref-8">8</a></sup>. <i>P. aeruginosa</i> is one of the six ESKAPE pathogens that are the major cause of nosocomial infections in the US and are a threat all over the world because of their capacity to become increasingly resistant to all available antibiotics<sup><a href="#ref-9">9</a></sup>. <i>P. aeruginosa</i> is equipped with a lowly permeable outer membrane and multiple transport systems, rendering it naturally resistant to many antimicrobial agents<sup><a href="#ref-10">10</a></sup>. In addition to its intrinsic resistance common to all <i>P. aeruginosa</i>, the bacterium has the extraordinary capacity to develop resistance to nearly all available antimicrobials<sup><a href="#ref-11">11</a></sup>. The most common underlying mechanisms in multidrug-resistant (MDR) and extensively drug-resistant (XDR) <i>P. aeruginosa</i> are alterations in porin channels, efflux pumps, target modifications, and β-lactamases (for example, AmpC and carbapenemases)<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>. Resistance may be acquired by the selection of mutations in chromosomal genes or horizontal uptake of resistance determinants. Of particular concern are mobile genomic islands and integrons encoding carbapenemases or extended-spectrum β-lactamases (ESBLs) frequently co-transferred with aminoglycoside-modifying enzyme determinants<sup><a href="#ref-14">14</a>,<a href="#ref-15">15</a></sup>.</p><p class="" id=d20924e252>This review deals with the current approaches to develop new modes of anti-pseudomonal therapies. The decision of major pharmaceutical companies to exit antibacterial research has triggered the formation of non-profit alliances that support academia, clinicians, and industry in the development of novel antimicrobials. For example, Combating Antibiotic Resistant Bacteria (CARB-X) (<a target=xrefwindow href="https://carb-x.org/" id=d20924e254>https://carb-x.org/</a>) is funded by the US Department of Health and Human Services, the National Institutes of Health, the Wellcome Trust, the Bill &amp; Melinda Gates Foundation, and Germany’s Federal Ministry of Education and Research. CARB-X is investing up to $550 million (USD) from 2016 to 2021 to accelerate the development of innovative antibiotics and other therapeutics, vaccines, and rapid diagnostics to address drug-resistant bacterial infections. Several companies have received funds from CARB-X to develop anti-pseudomonal agents, namely inhibitors of virulence factors and antibiotic potentiators<sup><a href="#ref-16">16</a></sup>. Support to develop novel drugs is also provided by the Innovative Medicines Initiative (IMI) funded jointly by the European Union and the European pharmaceutical industry. As described below, CARB-X and the IMI have been instrumental in speeding up the pre-clinical and clinical development of numerous anti-pseudomonal agents.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d20924e265>Antibiotics</h2><p class="" id=d20924e268>Antimicrobial chemotherapy is still the cornerstone of anti-pseudomonal treatment in clinical practice. <i>P. aeruginosa</i> is a naturally MDR organism, which may explain its success in becoming one of the most frequent nosocomial pathogens. Environmental <i>P. aeruginosa</i> strains are commonly susceptible to broad-spectrum penicillins and cephalosporins, aminoglycosides, monobactams, carbapenems, and fluoroquinolones. Since the 1980s, the intravenous combination therapy of piperacillin or ceftazidime with an aminoglycoside has been the standard of care to treat severe infections with <i>P. aeruginosa</i>, but the emergence of resistant organisms, particularly in the settings of intensive care or chronic persistence in vulnerable patient populations, has called for alternatives.</p><p class="" id=d20924e280>One strategy for the treatment of MDR <i>P. aeruginosa</i> has been the revival of colistin and polymyxin B, old drugs that had been abandoned for many years because of their significant toxicity and side effects. Within a few years of more active therapeutic use, a growing number of strains have meanwhile developed resistance against these last-line peptide antibiotics<sup><a href="#ref-17">17</a>,<a href="#ref-18">18</a></sup>. Mutations in various two-component systems activate the <i>arn</i> operon, which modifies the lipid A moiety of the lipopolysaccharide (LPS) through the addition of 4-amino-4-deoxy-L-arabinose, thereby rendering the bacterial cell resistant to the peptide antibiotic<sup><a href="#ref-17">17</a>,<a href="#ref-18">18</a></sup>.</p><p class="" id=d20924e303>An alternative strategy has been the development of molecules that overcome β-lactam antibiotic resistance. Two new cephalosporin-β-lactamase inhibitor combinations have recently been introduced into the clinic: ceftazidime-avibactam and ceftolozane-tazobactam<sup><a href="#ref-19">19</a></sup>. Avibactam readily inactivates the chromosomal β-lactamase of <i>P. aeruginosa</i> AmpC. Tazobactam is a less potent inhibitor of AmpC but this is compensated by the new antibiotic component in this combination, ceftolozane, which is only poorly hydrolyzed by AmpC.</p><p class="" id=d20924e313>At the time of this writing, more than 90% of <i>P. aeruginosa</i> isolates around the world seem to be susceptible to colistin, ceftazidime-avibactam, and ceftolozane-tazobactam<sup><a href="#ref-15">15</a>,<a href="#ref-20">20</a>–<a href="#ref-23">23</a></sup>. Resistance to the latter two antibiotic–antibiotic inhibitor combinations has been observed mainly in <i>P. aeruginosa</i> isolates that belong to the pandemic ST235 high-risk clone and carry novel isoforms of AmpD or ESBLs or both<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>.</p><p class="" id=d20924e340>Besides avibactam and tazobactam, other β-lactamase inhibitors—that is, relebactam<sup><a href="#ref-26">26</a>–<a href="#ref-29">29</a></sup>, zidebactam<sup><a href="#ref-30">30</a>,<a href="#ref-31">31</a></sup>, nacubactam<sup><a href="#ref-32">32</a></sup>, vaborbactam<sup><a href="#ref-28">28</a></sup>, VNRX-5133<sup><a href="#ref-33">33</a></sup>, and AAI101<sup><a href="#ref-26">26</a></sup>—are being tested in clinical trials.</p><p class="" id=d20924e374>An encouraging addition to the portfolio of anti-pseudomonal β<i>-</i>lactams is the siderophore cephalosporin cefiderocol<sup><a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>. Cefiderocol is structurally related to the cephalosporins ceftazidime and cefepime by sharing side chains that block recognition and inhibit hydrolysis by β-lactamases. The novelty resides in the extension of one side chain by a catechol 2-chloro-3,4-dihydroxybenzoic acid moiety. The catechol side chain enables ferric iron ion binding. The cefiderocol iron ion complex is recognized by active iron transport systems (such as PiuA) which transport cefiderocol across the outer membrane and to the periplasmic space<sup><a href="#ref-36">36</a></sup>. After dissociation of the complex, cefiderocol binds to penicillin binding proteins (PBP1a, PBP1b, PBP2, and PBP3) and inhibits peptidoglycan synthesis, causing cell death. Compared with the anti-pseudomonal agents that are currently available for use in humans, cefiderocol had the strongest activity against MDR <i>P. aeruginosa</i> strains. Of all β-lactams, cefiderocol has the most extended stability to hydrolysis by β-lactamases and its periplasmic entry via active iron transport systems overcomes β-lactam resistance associated with outer membrane permeability mutations in <i>P. aeruginosa</i><sup><a href="#ref-37">37</a></sup>.</p><p class="" id=d20924e400>Cefiderocol is more potent <i>in vitro</i> against MDR <i>P. aeruginosa</i> than ceftazidime-avibactam and ceftolozane-tazobactam<sup><a href="#ref-38">38</a></sup>. Cefiderocol showed activity against AmpC-overproducing strains, low affinity for chromosomal AmpC β-lactamases, and a low propensity of temporal induction of AmpC β-lactamases of <i>P. aeruginosa</i><sup><a href="#ref-39">39</a></sup>. Cefiderocol is active against carbapenem-non-susceptible isolates, including serine carbapenemase- and metallo-β-lactamase-producing strains<sup><a href="#ref-40">40</a>,<a href="#ref-41">41</a></sup>.</p><p class="" id=d20924e426>Carbapenem-resistant Gram-negative bacteria represent the highest priority for addressing global antibiotic resistance. Cefiderocol may address this problem—at least for some years to come. A recently completed phase II clinical trial demonstrated clinical efficacy and safety of intravenous cefiderocol compared with imipenem/cilastatin in patients with complicated urinary tract infections<sup><a href="#ref-35">35</a></sup>. Clinical trials of hospital-acquired pneumonia and carbapenem-resistant infections (ClinicalTrials.gov identifiers NCT02321800, NCT02714595, and NCT03032380) are ongoing.</p><p class="" id=d20924e433>Novel non-β-lactam antimicrobials have also been developed to target MDR organisms<sup><a href="#ref-42">42</a></sup>. Plazomicin is a sisomycin derivative that is unaffected by aminoglycoside-modifying enzymes. It was approved by the US Food and Drug Administration (FDA) for use in adults with complicated urinary tract infections. Its anti-pseudomonal activity is comparable to that of amikacin and less potent than that of tobramycin, indicating that this compound will probably not be very useful for the treatment of infections with <i>P. aeruginosa</i><sup><a href="#ref-42">42</a></sup>. The same argument applies even more so to the tetracyclines eravacycline and omadacyline, which demonstrate antimicrobial activity against many Gram-positive and Gram-negative bacteria but are not active against <i>P. aeruginosa</i><sup><a href="#ref-42">42</a></sup>. In contrast, two novel fluoroquinolones, finafloxacin<sup><a href="#ref-43">43</a>,<a href="#ref-44">44</a></sup> and delafloxacin<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>, which (depending on pH) exert anti-pseudomonal activity equivalent to or higher than that of ciprofloxacin, have recently become available.</p><p class="" id=d20924e467>Besides these analogues of classes of antimicrobials well known for their basic chemical structure and mode of antimicrobial action, anti-pseudomonal drugs that aim at a new target are being developed. Murepavadin, a 14–amino acid synthetic peptidomimetic, is a first-in-class antibiotic targeting outer membrane protein<sup><a href="#ref-46">46</a></sup>. During the biogenesis of the outer membrane, new LPS molecules are transported from their site of assembly on the inner membrane to the outer membrane by seven LPS transport proteins (LptA–G). The complex formed between the outer membrane protein LptD and the lipoprotein LptE is responsible for transporting LPS from the periplasmic side of the outer membrane to its final location on the cell surface. Murepavadin inhibits the LPS transport protein LptD in <i>P. aeruginosa</i>. Murepavadin was proven to be a very potent antibiotic highly specific to <i>P. aeruginosa</i>, including carbapenemase producers and ceftolozane/tazobactam-resistant and colistin-resistant strains. Murepavadin (96.7% of isolates susceptible) was more active than colistin (93.6%), followed by ceftolozane/tazobactam (70.6%) and tobramycin (47.5%)<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>. Two clinical trials have been evaluating the efficacy and safety of murepavadin in treating lower respiratory tract infections caused by <i>P. aeruginosa</i> (suspected or confirmed) among patients with ventilation-associated pneumonia or bronchiectasis unrelated to CF (ClinicalTrials.gov identifiers NCT02096315 and NCT02096328, respectively). However, by July 17, 2019, the studies were stopped because an unexpectedly high frequency of renal failures had been observed in study participants who had received murepavadin. The development of an aerosolized formulation of murepavadin for a topical application will not be affected by this decision.</p><p class="" id=d20924e491>Murepavadin is a specific weapon against <i>P. aeruginosa</i>, which sets it apart from the large pipeline of natural and synthetic antimicrobial peptides that act against multiple taxa, including <i>P. aeruginosa</i>. Several novel peptides with broad antimicrobial activity—for example, DGL13K<sup><a href="#ref-49">49</a></sup>, Mel4<sup><a href="#ref-50">50</a></sup>, melimine<sup><a href="#ref-50">50</a></sup>, cecropin B<sup><a href="#ref-51">51</a></sup>, LBP-2<sup><a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup>, Pse-T2<sup><a href="#ref-54">54</a></sup>, 6K-F17<sup><a href="#ref-55">55</a></sup>, MDP1<sup><a href="#ref-56">56</a></sup>, and MDP2<sup><a href="#ref-56">56</a></sup>—have recently been described.</p><p class="" id=d20924e540>Aerosolized anti-pseudomonal agents are the domain for the treatment of chronic airway infections of individuals with CF or bronchiectasis. Established options are the long-term inhalation with high-dose tobramycin<sup><a href="#ref-57">57</a>,<a href="#ref-58">58</a></sup>, colistin<sup><a href="#ref-59">59</a>–<a href="#ref-61">61</a></sup>, or aztreonam-lysine<sup><a href="#ref-62">62</a>–<a href="#ref-64">64</a></sup>. Emerging alternatives were the inhalation of liposomal amikacin<sup><a href="#ref-65">65</a></sup> and, more recently, the inhalation with dry powder<sup><a href="#ref-66">66</a>,<a href="#ref-67">67</a></sup> or liposomal<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup> ciprofloxacin or with liposomal levofloxacin<sup><a href="#ref-70">70</a></sup>. As described below, the clinical drug development programs had to face unforeseen obstacles unrelated to the proven anti-pseudomonal activity of the formulations <i>in vitro</i>.</p><p class="" id=d20924e590>Liposomal amikacin can penetrate within airway secretions and within <i>P. aeruginosa</i> biofilms, making it an attractive therapeutic option for chronic pulmonary infections. A phase II study with once-daily liposomal amikacin demonstrated acute tolerability, safety, biologic activity, and efficacy in CF patients with <i>P. aeruginosa</i> infection<sup><a href="#ref-71">71</a></sup>. However, apparently because of the results of a long-term rat inhalation carcinogenicity study, the FDA placed a clinical hold on the phase III clinical trials with this patient cohort by August 2017 and requested more safety data. Thirteen months later, the FDA approved inhalation with liposomal amikacin for the treatment of lung disease with <i>Mycobacterium avium</i> complex (MAC) in patients with refractory disease. Thus, at least until the time of this writing, the journey ended with a new therapy for MAC but not for <i>P. aeruginosa</i>.</p><p class="" id=d20924e609>Two phase III, double-blind, placebo-controlled trials—RESPIRE 1<sup><a href="#ref-67">67</a></sup> and RESPIRE 2<sup><a href="#ref-66">66</a></sup>—examined the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-CF bronchiectasis who had experienced two or more exacerbations in the previous year and pre-defined bacteria in sputum, including <i>P. aeruginosa</i>, as a major pathogen. These two trials represent the largest clinical trial program ever conducted in bronchiectasis. RESPIRE 1 largely enrolled across Europe, North and South America, Australia, and Japan, whereas RESPIRE 2 focused on Asia and Eastern Europe. Patients received twice-daily ciprofloxacin DPI 32.5 mg or placebo in 14- or 28-day on/off treatment cycles for 48 weeks. The 14-day on/off treatment cycles in RESPIRE 1 significantly prolonged time to first exacerbation and reduced the frequency of exacerbations. The same trends were seen in the 14-day cycle in RESPIRE 2 and the 28-day cycles but did not achieve significance. When the data were pooled, an average 24% reduction in exacerbations was calculated. Experts who commented on the outcome of the trials concluded that aerosolized dry powder ciprofloxacin is most likely to be of benefit in selected patients with poorly controlled disease and very frequent exacerbations<sup><a href="#ref-72">72</a></sup>.</p><p class="" id=d20924e627>An alternative formulation to dry powder is the encapsulation of drug into liposomes. Two randomized, double-blind, placebo-controlled, phase 3 trials—ORBIT-3 and ORBIT-4—investigated the safety and efficacy of inhaled liposomal ciprofloxacin<sup><a href="#ref-69">69</a></sup>. The more than 500 study participants had had two or more pulmonary exacerbations treated with antibiotics in the prior 12 months, had non-CF bronchiectasis, and had a history of chronic <i>P. aeruginosa</i> lung infection. Compared with placebo, inhalation with liposomal ciprofloxacin led to a significantly longer median time to first pulmonary exacerbation in the ORBIT-4 but not in the ORBIT-3 trial. In a pooled analysis of data from the two trials, median times to first pulmonary exacerbation were 157 days in the placebo group and 222 days in the verum group, a non-statistically significant difference of 65 days (0.82, 95% confidence interval (CI) 0.65–1.02; <i>P</i> = 0.074).</p><p class="" id=d20924e640>For both the two RESPIRE and ORBIT trials, the results were not replicated. The discrepant outcome was attributed to differences in clinical practice and the vast ethnic, geographic, and endo-phenotypic heterogeneity of bronchiectasis<sup><a href="#ref-72">72</a></sup>. Future trials should address these differences across the globe and should thoroughly characterize the endo-phenotype of individual patients in order to identify the patient groups which benefit from specific modes of anti-pseudomonal treatment. Patient stratification within this highly heterogeneous group of patients makes sense in light of the experience with CF, which is a monogenic disorder of Caucasians. Most clinical studies on anti-pseudomonal chemotherapy in this more homogeneous patient population met their primary endpoints with smaller cohorts than the RESPIRE and ORBIT trials.</p><p class="" id=d20924e648>In randomized controlled trials, monotherapy with an aerosolized anti-pseudomonal drug has been proven to be an effective measure to suppress chronic airway infections with <i>P. aeruginosa</i> in CF<i>.</i> Comparable data on inhaled combination therapy are still missing. <i>P. aeruginosa</i> biofilms grown <i>in vitro</i> typically consist of a stalk-forming subpopulation situated in the deeper layer with low metabolic activity and a cap-forming subpopulation in the upper layer with metabolically active cells<sup><a href="#ref-73">73</a></sup>. Colistin preferentially kills the stalk subpopulation, whereas the cap-forming subpopulation is susceptible to the aminoglycoside tobramycin<sup><a href="#ref-74">74</a></sup>. Owing to this observation in biofilms as models for the sessile lifestyle of <i>P. aeruginosa</i> in CF airways, the sequential therapy with inhaled tobramycin and colistin was examined in an observational study with 41 CF patients with chronic <i>P. aeruginosa</i> infection<sup><a href="#ref-75">75</a></sup>. Treatment was well tolerated and significantly improved patients’ lung function. An alternative to colistin-tobramycin may be aztreonam-tobramycin. When biofilms were grown in flow cells, the alternation of tobramycin and aztreonam potentiated the bactericidal effect and the reduction in bacterial biomass<sup><a href="#ref-76">76</a></sup>.</p><p class="" id=d20924e686>Meanwhile, combination inhalation therapy has become routine in clinical practice, but besides the open-label exploratory study mentioned above, no clinical trials have yet been published. More clinical data about the efficacy of systemic combination therapy are available. For example, an 11-year single-center retrospective analysis of the treatment of <i>P. aeruginosa</i> bloodstream infections revealed that survival of patients receiving combination therapy (β-lactam-aminoglycoside or β<i>-</i>lactam-quinolone) was significantly higher than that of patients receiving β-lactam monotherapy<sup><a href="#ref-77">77</a></sup>. A recently published meta-analysis compared the outcome of empirical non-optimized double β-lactam combination therapy versus β<i>-</i>lactam plus aminoglycoside<sup><a href="#ref-78">78</a></sup>. In the 164 cases from 13 randomized clinical trials reported between 1972 and 1993, a response to <i>P. aeruginosa</i> was achieved in 58.5% for double β-lactam and 60.6% for β-lactam-aminoglycoside. The two regimens achieved similar clinical and microbiological responses, but nephrotoxicity and ototoxicity were significantly lower with double β<i>-</i>lactam combination therapy. These metadata are from a time period before broad-spectrum antibiotics were widely introduced into the clinic. Nevertheless, they tell us that double β-lactams may be a useful therapeutic option because synergy may arise from the complementary inactivation of sets of PBPs<i>.</i> </p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d20924e719>Modulators of bacterial cell wall, transport, signaling, or virulence</h2><p class="" id=d20924e722>Mucoid alginate-overproducing <i>P. aeruginosa</i> strains are a phenotypical hallmark of chronic airway infections in individuals with CF. Bacterial alginate is made of alternating blocks of mannuronate homooligomers and mannuronate-guluronate heterooligomers, whereas the algal alginate also contains guluronate homooligomers. Algal-derived alginate oligomers enriched in guluronate homooligomers (oligoG) reduce the viscosity of sticky biofilms and potentiate anti-bacterial and anti-fungal compounds. OligoG DPI is being tested in IMI-supported phase 2 clinical trials whether they improve lung function and respiratory symptoms in patients with CF.</p><p class="" id=d20924e728>The intrinsic multidrug resistance of <i>P. aeruginosa</i> is partly based on its low outer membrane permeability. By 1983, Vaara and Vaara introduced the concept of outer membrane–disorganizing sensitizers that make the outer membrane more permeable to amphiphilic and hydrophobic compounds<sup><a href="#ref-79">79</a></sup>. For example, the non-bactericidal polymyxin B nonapeptide sensitized <i>P. aeruginosa</i> strains 2- to 40-fold to ciprofloxacin, norfloxacin, and ofloxacin and 80- to 200-fold to the parent compound nalidixic acid, indicating that the higher anti-pseudomonal activity of fluoroquinolones compared with nalidixic acid was based not only on the more efficient inhibition of the DNA gyrase but also on a higher outer membrane permeability<sup><a href="#ref-80">80</a></sup>. Now more than 30 years after the first report of three outer membrane sensitizers, the approved anti-protozoal drug pentamidine<sup><a href="#ref-81">81</a></sup> and the polymyxin B analogues SPR206 and SPR741<sup><a href="#ref-82">82</a>,<a href="#ref-83">83</a></sup> are in pre-clinical and clinical studies to re-fuel the anti-Pseudomonas pipeline.</p><p class="" id=d20924e757><i>P. aeruginosa</i> uses quorum sensing, including the elastase (Las), rhamnolipid (Rhl), and Pseudomonas quinolone signal (PQS) systems, to regulate and coordinate population-wide group behaviors in infection processes like biofilm formation and the concerted secretion of virulence factors. Pathoblockers of the quorum sensing system abolish pathogenic features without affecting cell viability, providing the basis for a lower drug-induced selection pressure<sup><a href="#ref-84">84</a>–<a href="#ref-87">87</a></sup>. Potent inhibitors of all known quorum sensing systems have been identified, but none of the novel compounds such as NX-As-401 (<a target=xrefwindow href="http://www.neembiotech.com/" id=d20924e768>www.neembiotech.com</a>) has yet made it into clinical trials. The exceptions are the well-known macrolide antibiotics. In the late 1980s, Japanese physicians reported that the chronic administration of erythromycin, clarithromycin, and azithromycin improved the clinical symptoms and prognosis of patients with chronic <i>P. aeruginosa</i> infections<sup><a href="#ref-88">88</a></sup>. Azithromycin does not kill <i>P. aeruginosa</i> but inhibits protein biosynthesis and quorum sensing<sup><a href="#ref-89">89</a></sup>. Azithromycin is now widely used for the treatment of chronic airway infections with <i>P. aeruginosa</i> in patients with COPD, bronchiectasis, or CF. Within the setting of the ICU, azithromycin showed a trend to prevent ventilation-associated pneumonia in intubated patients and significantly reduced the activation of quorum sensing–regulated virulence traits<sup><a href="#ref-90">90</a></sup>.</p><p class="" id=d20924e794>Iron metabolism is another highly topical target of anti-pseudomonal drug development. Gallium is an iron mimetic<sup><a href="#ref-91">91</a>–<a href="#ref-95">95</a></sup>. Ga<sup>3+</sup> has an ionic radius nearly identical to that of ferric iron Fe<sup>3+</sup> and hence can replace iron in Fe<sup>3+</sup>-dependent biological systems. Unlike Fe<sup>3+</sup>, Ga<sup>3+</sup> is not reduced under physiological conditions and thus inactivates iron-mediated redox cycling<sup><a href="#ref-91">91</a>–<a href="#ref-93">93</a></sup>. Gallium inhibited <i>P. aeruginosa</i> growth and biofilm formation and killed planktonic and biofilm bacteria <i>in vitro</i><sup><a href="#ref-91">91</a>,<a href="#ref-92">92</a>,<a href="#ref-94">94</a></sup> and increased survival in a murine infection model<sup><a href="#ref-91">91</a>,<a href="#ref-92">92</a>,<a href="#ref-95">95</a></sup>. Intravenous gallium treatment improved lung function in CF patients with chronic <i>P. aeruginosa</i> lung infection in a preliminary phase 1 clinical trial<sup><a href="#ref-95">95</a></sup>.</p><p class="" id=d20924e861>Neutralization of virulence effectors is another currently pursued approach to combat infections with <i>P. aeruginosa.</i> Some programs are supported by the CARB-X alliance. For example, inhibitors are developed against the <i>P. aeruginosa</i> LasB elastase (<a target=xrefwindow href="https://antabio.com/programs" id=d20924e869>https://antabio.com/programs</a>), thereby targeting the bacterium’s ability to evade the immune system and cause disease and, when given alongside antibiotics, helping to clear <i>P. aeruginosa</i> infections. Other programs have focused on the machinery and virulence effectors of the type III secretion system. Phenoxyacetamide inhibitors target the needle protein PscF that delivers the virulence effectors into the host cell<sup><a href="#ref-96">96</a>,<a href="#ref-97">97</a></sup>. Alternatively, monoclonal antibodies were generated against the PcrV protein that forms the tip of the injectosome complex<sup><a href="#ref-98">98</a></sup>. Intravenous KB001-A, an anti-PcrV PEGylated monoclonal antibody fragment, showed limited efficacy in CF patients infected with <i>P. aeruginosa</i><sup><a href="#ref-99">99</a></sup>. The repeated administration of KB001-A over 16 weeks was associated with a small improvement of lung function and decrease of sputum inflammatory markers but did not prolong the time-to-need for antibiotics for worsening respiratory signs and symptoms<sup><a href="#ref-99">99</a></sup>. Bispecific antibodies that block multiple evasion and subversion mechanisms in tandem may be more efficacious<sup><a href="#ref-100">100</a></sup>. In a murine bacteremic model of <i>P. aeruginosa</i> infection, the bispecific therapeutic antibody MEDI3902, targeting PcrV and the Psl exopolysaccharide, was shown to efficiently enhance neutrophil uptake, phagosome acidification, and bacterial killing<sup><a href="#ref-101">101</a></sup>. After completion of a phase 1 study<sup><a href="#ref-102">102</a></sup>, passive immunization with MEDI3902 (renamed Gremubamab) is currently in phase 2b development for prevention of nosocomial <i>P. aeruginosa</i> pneumonia in patients undergoing mechanical ventilation (EVADE study funded by the IMI).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d20924e920>Novel formulations for anti-pseudomonal drug delivery</h2><p class="" id=d20924e923>Impaired penetration of antimicrobials through bacterial biofilms is one of the reasons for the failure of anti-pseudomonal therapy of burn wounds and chronic lung infections. Encapsulation of antimicrobials in nanocarriers may facilitate drug diffusion within the sticky biofilm matrix, protect the drug from unwanted degradation, confer controlled drug release, and increase uptake by the drug target. Anti-pseudomonal drugs such as ciprofloxacin<sup><a href="#ref-103">103</a>–<a href="#ref-105">105</a></sup>, meropenem<sup><a href="#ref-106">106</a></sup>, tobramycin<sup><a href="#ref-107">107</a>,<a href="#ref-108">108</a></sup>, gentamicin<sup><a href="#ref-109">109</a></sup>, or amikacin<sup><a href="#ref-110">110</a></sup> were encapsulated into liposomes or loaded into nanoparticles. The drug delivery systems were diverse in chemical nature and include anionic liposomes<sup><a href="#ref-105">105</a>,<a href="#ref-106">106</a>,<a href="#ref-109">109</a></sup>, poly(lactic-co-glycolic) acid nanoparticles<sup><a href="#ref-110">110</a>,<a href="#ref-111">111</a></sup>, water-soluble chitosan oligosaccharide conjugates<sup><a href="#ref-112">112</a></sup>, oil-in-water cross-linked polymeric nanocomposites<sup><a href="#ref-113">113</a></sup>, graphen-oxide conjugates<sup><a href="#ref-107">107</a></sup>, or solid lipid nanoparticles<sup><a href="#ref-114">114</a></sup>, to name just a few. Alternatively, dry powders<sup><a href="#ref-103">103</a>,<a href="#ref-104">104</a>,<a href="#ref-108">108</a>,<a href="#ref-115">115</a></sup> or hydrogels<sup><a href="#ref-116">116</a>–<a href="#ref-119">119</a></sup> were formulated or wound dressings were coated with a topical antimicrobial such as silver oxynitrate<sup><a href="#ref-120">120</a></sup>. Irrespective of the chosen formulation, most published articles report that their formulation penetrates through mucus and biofilms, is more effective than the antimicrobial alone to eradicate biofilm formation, and mitigates infection and disease progression.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d20924e1014>Vaccines</h2><p class="" id=d20924e1017>The provision of an effective vaccine to protect patient populations at risk from an infection with <i>P. aeruginosa</i> has been on the agenda of Pseudomonas researchers for many decades, but there are no licensed vaccines at present. In the 1990s, the Swiss Serum and Vaccine Institute developed an octavalent <i>P. aeruginosa</i> O-polysaccharide-toxin A conjugate vaccine for immunization of healthy <i>P. aeruginosa</i>–negative patients with CF<sup><a href="#ref-121">121</a></sup>. The persistence of high-affinity antibodies among immunized patients correlated with a significantly lower rate of infection after 4 to 6 years of observation. The vaccine was well received by the European CF community. Patients at my CF center regularly travelled to Bern, Switzerland, to receive boosters every two to three years until the stock was used up. A few years later, Döring <i>et al</i>. conducted a double-blind, placebo-controlled, multicenter trial with a flagella vaccine demonstrating that active immunization of patients with CF lowers the risk for infection with <i>P. aeruginosa</i><sup><a href="#ref-122">122</a></sup>. The third approach was the 20-year-long development of vaccines based on OprF-OprI outer membrane fusion proteins as antigen<sup><a href="#ref-123">123</a></sup>. In the last pilot study, published in 2010, human volunteers were vaccinated with a systemic, nasal, or oral live vaccine based on attenuated live Salmonella (strains CVD908 and Ty21a), followed by a systemic booster<sup><a href="#ref-124">124</a></sup>. Systemic and mucosal vaccines induced a comparable rise of serum antibody titers, but only nasal and oral vaccinations elicited a significant rise of IgA and IgG antibodies in the lower airways. At that time, the authors concluded that nasal and oral OprF-OprI vaccines were promising candidates for development of anti-pseudomonal immunization through inducing a specific antibody response in the lung.</p><p class="" id=d20924e1051>These old data, including small clinical trials on burns and CF, provided evidence that a vaccine could be an effective measure to prevent infections with <i>P. aeruginosa.</i> Hence, the recombinant OprF-OprI vaccine was tested in a randomized, placebo-controlled, double-blind phase II/III study<sup><a href="#ref-125">125</a></sup>, which was conducted in 800 mechanically ventilated ICU patients at 52 trial sites in six European countries. Patients were vaccinated twice with either the <i>P. aeruginosa</i> vaccine candidate or a placebo at a 7-day interval in conjunction with standard-of-care treatments for ICU patients. Although the trial confirmed good immunogenicity and an acceptable safety profile of the vaccine candidate, the primary endpoint of the phase II/III trial was not met. Therefore, findings from a previous phase II study that had shown a strong reduction in all-cause mortality were not confirmed.</p><p class="" id=d20924e1064>The outcome of this largest-ever trial performed on a Pseudomonas vaccine was disappointing. Nevertheless, there are encouraging new data on other antigens. For example, a live <i>aroA-aroB</i> attenuated <i>Salmonella</i> vaccine that uses a fusion between the <i>P. aeruginosa</i> type III secretion antigen PcrV expressed under the control of the sseA promoter and the <i>S. enterica</i> type III secretion effector protein SseJ has been constructed<sup><a href="#ref-126">126</a></sup>. Compared with control mice, mice immunized with attenuated <i>Salmonella</i> expressing this fusion had lower serum levels of pro-inflammatory cytokines and reduced bacterial loads in the spleen and lungs after <i>P. aeruginosa</i> infection. Importantly, in this model, immunized mice also showed significantly enhanced survival. Another novel strategy is the design of live-attenuated whole cell vaccines based on D-glutamate auxotrophy<sup><a href="#ref-127">127</a></sup>. The enzyme glutamate racemase MurI converts the amino acid L-glutamate into its enantiomer D-glutamate, which is an essential component of peptidoglycan. In-frame deletion of the <i>murI</i> gene generated a live-attenuated <i>P. aeruginosa</i> auxotrophic strain that, upon local or systemic administration, triggered appropriate cellular immune responses and production of specific and cross-reactive antibodies in the vaccinated murine hosts and conferred long-term survival against lethal infections with <i>P. aeruginosa</i> but, on the other hand, was rapidly eliminated from the host without causing disease. Other groups showed protection in murine infection models by using the iron acquisition protein HitA<sup><a href="#ref-128">128</a></sup>, PA5340 combined with PA3526-MotY<sup><a href="#ref-129">129</a></sup>, PcrV with CpG oligodeoxynucleotide<sup><a href="#ref-130">130</a></sup>, or the pilus proteins PilQ and PilA<sup><a href="#ref-131">131</a></sup> as vaccine antigens.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d20924e1124>Phage therapy</h2><p class="" id=d20924e1127>Given that antibiotic resistance is an increasing threat not only to human health but also to the production of food and to sustainable development, phage therapy is regaining interest as an alternative or addition to antibiotic therapy for the treatment of bacterial infections<sup><a href="#ref-132">132</a></sup>. Phage therapy was abandoned in many countries with the advent of antibiotic therapy but has been continually developed in Eastern European countries with centers in Warsaw, Poland, and Tbilisi, Georgia<sup><a href="#ref-133">133</a></sup>. Shotgun metagenome sequencing revealed that the phage cocktails sold in pharmacies in Georgia and Russia contained anti-pseudomonal phages<sup><a href="#ref-134">134</a></sup>. A few case reports from Belgium and the US communicated the successful treatment of infections with MDR <i>P. aeruginosa</i><sup><a href="#ref-135">135</a>,<a href="#ref-136">136</a></sup>.</p><p class="" id=d20924e1151>Early this year, the outcome of the first clinical study on phage therapy was reported<sup><a href="#ref-137">137</a></sup>. The study, conducted as a randomized controlled double-blind trial, compared the tolerability and efficacy of a cocktail of lytic anti-<i>P. aeruginosa</i> bacteriophages with standard of care for patients with burns. The primary endpoint—the median time to sustained reduction in bacterial burden—was reached in 47 hours in the standard-of-care group (hazard ratio 0.29, 95% CI 0.10–0.79; <i>P</i> = 0.018) versus 144 hours (95% CI 48–not reached) in the group that received the phages. The finding that a standardized phage cocktail decreased bacterial burden in burn wounds more slowly than the standard of care is a strong indication that phage cocktails of fixed composition could unfavorably interfere with the evolutionary race between phage and bacterium by selecting phage resistance in the heterogeneous bacterial populations that vary from patient to patient. The personalized approach of choosing phages that specifically target the Pseudomonas bacteria in the individual host habitat may be more effective, although it will require rethinking of the regulatory agencies.</p><p class="" id=d20924e1164>Research is very active in the pre-clinical arena. Practical themes are the setup of efficacious and safe antibacterial phage cocktails, the design of clever infection models, and the development of phages as adjuvants of antibiotic therapy. More importantly, if we want to make phage therapy a success, we need an in-depth understanding of how the mutual evolutionary race of attack and resistance between phage and bacterium takes place. Phages are, in principle, a smart anti-pseudomonal weapon. They specifically target a narrow spectrum of hosts, self-amplify, kill antibiotic-resistant strains, and have limited immunological effects in humans. However, it will not be a global anti-pseudomonal weapon. During chronic infection, <i>P. aeruginosa</i> may modify or delete all of its phage receptors. The author noticed that the majority of <i>P. aeruginosa</i> clones that persisted for five years or more in a CF lung had become pan-resistant to phages.<i></i> </p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d20924e1178>Hygienic measures</h2><p class="" id=d20924e1181><i>P. aeruginosa</i> is responsible for a wide range of acquired infections in critically ill patients. Microbiological monitoring according to Clinical and Laboratory Standards Institute standards, antimicrobial stewardship, and infection control programs, including environmental cleaning and disinfection, hand hygiene, and education of personnel, have been demonstrated to prevent the development of resistance in <i>P. aeruginosa</i><sup><a href="#ref-138">138</a></sup>. Prophylactic antibiotic days and inadequate empiric antibiotic therapy are independent major risk factors for the emergence of MDR ventilator-associated pneumonia in the ICU<sup><a href="#ref-139">139</a></sup>. Thus, prolonged exposure to unnecessary antibiotics should be avoided.</p><p class="" id=d20924e1196>In the hospital setting, <i>P. aeruginosa</i> may contaminate sanitary facilities, humid medical devices, aqueous solutions, soaps, and detergents<sup><a href="#ref-140">140</a></sup>. For example, recently published case reports identified sinks or flexible endoscopes as reservoirs for nosocomial transmission of <i>P. aeruginosa</i><sup><a href="#ref-141">141</a>,<a href="#ref-142">142</a></sup>. Sinks in hospitals are regularly contaminated with <i>P. aeruginosa</i>. Opening of water taps generates aerosols containing <i>P. aeruginosa</i> sink organisms that contaminate the faucet and hands during hand washing<sup><a href="#ref-140">140</a></sup>. Installation of filters under all water faucets has been shown to prevent bacterial contamination of tap water<sup><a href="#ref-143">143</a></sup>.</p><p class="" id=d20924e1230>In the context of CF, patient-to-patient transmissions of <i>P. aeruginosa</i> were reported from CF clinics, summer camps, and rehabilitation centers<sup><a href="#ref-5">5</a>,<a href="#ref-144">144</a></sup>. Transmissible epidemic clones spread at CF clinics in Australia, Canada, Denmark, The Netherlands, and the UK<sup><a href="#ref-5">5</a></sup>. Hence, infection prevention and control practices have been introduced into CF clinics encompassing education, temporal separation of <i>P. aeruginosa</i>–positive and <i>P. aeruginosa</i>–negative patients, hand and cough hygiene, and cleaning and disinfection of equipment<sup><a href="#ref-145">145</a></sup>. Retrospective and prospective observational studies performed after the introduction of cohort segregation have demonstrated decreases in the numbers of prevalent and incident cases of epidemic <i>P. aeruginosa</i> infections<sup><a href="#ref-5">5</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d20924e1268>Enhancement of host defense</h2><p class="" id=d20924e1271>Active immunization of vulnerable patient groups is the classic approach to prevent microbial infection. But in real-life situations such as an acute illness requiring hospitalization, the time span to mount protective antibody titers may be too long to be clinically meaningful.</p><p class="" id=d20924e1274>In the ICU, treatment with antibiotics often is live-saving but is also a major risk factor for subsequent nosocomial lung infection with <i>P. aeruginosa</i>. A recent study by Robak <i>et al</i>. demonstrates that the ICU patient’s susceptibility to secondary Pseudomonas infection is caused by antibiotic-associated secondary IgA deficiency<sup><a href="#ref-146">146</a></sup>. Depletion of the resident microbiota by broad-spectrum antibiotic treatment inhibits the stimulation of pulmonary IgA production mediated by microbiota-dependent activation of Toll-like receptors and the tumor necrosis factor (TNF) family cytokine APRIL (a proliferation-inducing ligand). If antibiotic-pretreated mice received IgA by the nasal route, their antibacterial defense against <i>P. aeruginosa</i> was partially restored. The authors propose that ICU patients on broad-spectrum antimicrobial therapy may benefit from prophylactic or therapeutic pulmonary IgA administration or both.</p><p class="" id=d20924e1290>Cell-based treatment is another emerging option to target airway infections with <i>P. aeruginosa</i><sup><a href="#ref-147">147</a></sup>. Therapeutic phagocytes such as macrophages can be produced from induced pluripotent stem cells (iPSCs) in industry-compatible, stirred-tank bioreactors. iPSC macrophages rescued mice from <i>P. aeruginosa</i>-mediated acute infections of the lower respiratory tract within 4 to 8 hours after intra-pulmonary transplantation and reduced bacterial load<sup><a href="#ref-147">147</a></sup>. This type of cell therapy may become an option for the treatment of congenital or acquired immune deficiency.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d20924e1309>Conclusions</h2><p class="" id=d20924e1312>The ESKAPE pathogens are the tip of the iceberg of the global antibiotic crisis. Many regions in the world now face infections with <i>P. aeruginosa</i> that is colistin- or carbapenem-resistant or both. Fortunately, the traditional approach to develop derivatives of validated scaffolds is still promising. The novel β-lactam inhibitors and siderophore cephalosporin are active against almost all current <i>P. aeruginosa</i>. The modification and combination of lead modules that tackle well-characterized bacterial targets constitute a rather safe approach to come up with an antimicrobial that will show efficacy and safety in clinical trials. The development of compounds against novel targets should be more rewarding in the long run. However, as we now experience with the currently most potent anti-pseudomonal agent, murepavadin<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>, the risk of off-target side effects is high and the compound may fail in clinical trials.</p><p class="" id=d20924e1328>Pathoblockers have finally come of age<sup><a href="#ref-81">81</a>,<a href="#ref-84">84</a>–<a href="#ref-87">87</a></sup>. Ten to forty years after the proof-of-principle experiments showing that small molecules may reduce fitness or virulence of <i>P. aeruginosa</i> without being bactericidal themselves were published<sup><a href="#ref-79">79</a>,<a href="#ref-98">98</a>,<a href="#ref-148">148</a></sup>, the first sensitizers are now being examined in clinical studies<sup><a href="#ref-83">83</a></sup>. For example, the iron biomimetic gallium attacks <i>P. aeruginosa</i> at its metabolic achilles’ heel<sup><a href="#ref-91">91</a>–<a href="#ref-95">95</a></sup>. The outcome of the first clinical study is encouraging<sup><a href="#ref-95">95</a></sup>; however, we still do not know whether gallium will drive <i>P. aeruginosa</i> cells into an iron deficiency status that may promote the adverse production of virulence factors<sup><a href="#ref-149">149</a></sup>.</p><p class="" id=d20924e1380>Given the threat of bacteria that are pan-resistant to the patient’s <i>P. aeruginosa</i> isolates, phage therapy is re-emerging as an attractive alternative to treat infections with <i>P. aeruginosa.</i> The outcome of the first high-standard clinical trial, published earlier this year, taught us that predetermined phage cocktails will probably not be the solution<sup><a href="#ref-137">137</a></sup>. Some <i>P. aeruginosa</i> strains will not be susceptible or will rapidly become resistant to the administered phages. To make phage therapy globally efficacious, we need a personalized approach as was recently demonstrated for a life-threatening infection with <i>Mycobacterium abscessus</i><sup><a href="#ref-150">150</a></sup>. Phage cocktails should be formulated on a case-by-case basis to specifically target of phage therapy. However, phage therapy will leave its niche only if the regulatory agencies change the legal rules and permit personalized medicine on a large scale.</p><p class="" id=d20924e1402>The development of antimicrobials is the classic approach to fight infections with <i>P. aeruginosa</i>. Only recently, the scientific community started to adopt the concept that the enhancement of host defense may be a promising alternative to conquer a nosocomial pathogen that causes severe infections in vulnerable populations but is more or less innocent for the healthy immunocompetent host. Relying on clinical experience in the ICU of the often disastrous course of secondary Pseudomonas pneumonias, researchers are becoming aware of the importance of the interplay between immune status and microbiome to contain this nosocomial pathogen<sup><a href="#ref-146">146</a></sup>. The enhancement of innate and adaptive immunity is a promising approach to vanquish MDR and XDR <i>P. aeruginosa.</i> Bispecific therapeutic antibodies<sup><a href="#ref-101">101</a>,<a href="#ref-102">102</a></sup> and local transfer of isogenic iPSC-derived immune cells<sup><a href="#ref-147">147</a></sup> could become the weapons of the future to prevent the fatal outcome of <i>P. aeruginosa</i> pneumonia and sepsis in ICU patients.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d20924e1433>Abbreviations</h2><p class="" id=d20924e1436>CARB-X, Combating Antibiotic Resistant Bacteria; CF, cystic fibrosis; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DPI, dry powder for inhalation; ESBL, extended-spectrum β-lactamase; FDA, US Food and Drug Administration; ICU, intensive care unit; IMI, Innovative Medicines Initiative; iPSC, induced pluripotent stem cell; Las, elastase; LPS, lipopolysaccharide; Lpt, lipopolysaccharide transporting protein; MAC, <i>Mycobacterium avium</i> complex; MDR, multidrug-resistant; OligoG, oligomers enriched in guluronate homooligomers; PBP, penicillin binding protein; XDR, extensively drug resistant</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d20924e1 class=n-a></a><h2 class=main-title id=d21381>Grant information</h2><p>Work in the author’s laboratory is supported by the Deutsche Forschungsgemeinschaft (DFG) (Collaborative Research Centre 900, projects A2 and Z1, grant 158989968; Germany’s Excellence Strategy – EXC 2155 “RESIST” – project ID 39087428) and the Bundesministerium für Bildung und Forschung (BMBF) (German Center for Lung Research, Disease Area Cystic Fibrosis at BREATH, grant 82DZL002A1). </p><p>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></div><div class=back-section><a name=d20924e1446 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d21895>References</h2><div class="section ref-list"><a name=d20924e1446 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d20924e1453 class=n-a></a>Teweldemedhin M, Gebreyesus H, Atsbaha AH, <i> et al.</i>: Bacterial profile of ocular infections: a systematic review. <i>BMC Ophthalmol.</i> 2017; <b>17</b>(1): 212. <a target=xrefwindow id=d20924e1464 href="http://www.ncbi.nlm.nih.gov/pubmed/29178851">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1467 href="https://doi.org/10.1186/s12886-017-0612-2">Publisher Full Text </a> | <a target=xrefwindow id=d20924e1471 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5702129">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d20924e1480 class=n-a></a>Glik J, Łabuś W, Kitala D, <i> et al.</i>: 2000 patient retrospective assessment of a new strategy for burn wound management in view of infection prevention and treatment. <i>Int Wound J.</i> 2018; <b>15</b>(3): 344–9. <a target=xrefwindow id=d20924e1491 href="http://www.ncbi.nlm.nih.gov/pubmed/29243368">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1494 href="https://doi.org/10.1111/iwj.12871">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d20924e1503 class=n-a></a>Koulenti D, Lisboa T, Brun-Buisson C, <i> et al.</i>: Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. <i>Crit Care Med.</i> 2009; <b>37</b>(8): 2360–8. <a target=xrefwindow id=d20924e1514 href="http://www.ncbi.nlm.nih.gov/pubmed/19531951">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1517 href="https://doi.org/10.1097/CCM.0b013e3181a037ac">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d20924e1526 class=n-a></a>Maraolo AE, Cascella M, Corcione S, <i> et al.</i>: Management of multidrug-resistant <i>Pseudomonas aeruginosa</i> in the intensive care unit: state of the art. <i>Expert Rev Anti Infect Ther.</i> 2017; <b>15</b>(9): 861–71. <a target=xrefwindow id=d20924e1540 href="http://www.ncbi.nlm.nih.gov/pubmed/28803496">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1544 href="https://doi.org/10.1080/14787210.2017.1367666">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d20924e1553 class=n-a></a>Parkins MD, Somayaji R, Waters VJ: Epidemiology, Biology, and Impact of Clonal <i>Pseudomonas aeruginosa</i> Infections in Cystic Fibrosis. <i>Clin Microbiol Rev.</i> 2018; <b>31</b>(4): pii: e00019-18. <a target=xrefwindow id=d20924e1564 href="http://www.ncbi.nlm.nih.gov/pubmed/30158299">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1567 href="https://doi.org/10.1128/CMR.00019-18">Publisher Full Text </a> | <a target=xrefwindow id=d20924e1571 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6148191">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d20924e1581 class=n-a></a>Wilson R, Aksamit T, Aliberti S, <i> et al.</i>: Challenges in managing <i>Pseudomonas aeruginosa</i> in non-cystic fibrosis bronchiectasis. <i>Respir Med.</i> 2016; <b>117</b>: 179–89. <a target=xrefwindow id=d20924e1595 href="http://www.ncbi.nlm.nih.gov/pubmed/27492530">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1599 href="https://doi.org/10.1016/j.rmed.2016.06.007">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d20924e1608 class=n-a></a>Rohde GGU, Welte T: [<i>Pseudomonas aeruginosa</i> infections in chronic obstructive pulmonary disease: Role of long-term antibiotic treatment]. <i>Internist (Berl).</i> 2017; <b>58</b>(11): 1142–9. <a target=xrefwindow id=d20924e1619 href="http://www.ncbi.nlm.nih.gov/pubmed/28983645">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1622 href="https://doi.org/10.1007/s00108-017-0332-y">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d20924e1631 class=n-a></a>Balabanova Y, Gilsdorf A, Buda S, <i> et al.</i>: Communicable diseases prioritized for surveillance and epidemiological research: results of a standardized prioritization procedure in Germany, 2011. <i>PLoS One.</i> 2011; <b>6</b>(10): e25691. <a target=xrefwindow id=d20924e1642 href="http://www.ncbi.nlm.nih.gov/pubmed/21991334">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1645 href="https://doi.org/10.1371/journal.pone.0025691">Publisher Full Text </a> | <a target=xrefwindow id=d20924e1649 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3186774">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d20924e1658 class=n-a></a>Lupo A, Haenni M, Madec JY: Antimicrobial Resistance in <i>Acinetobacter</i> spp. and <i>Pseudomonas</i> spp. <i>Microbiol Spectr.</i> 2018; <b>6</b>(3). <a target=xrefwindow id=d20924e1672 href="http://www.ncbi.nlm.nih.gov/pubmed/30101740">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1676 href="https://doi.org/10.1128/microbiolspec.ARBA-0007-2017">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1102233"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e1685 class=n-a></a>Fajardo A, Martínez-Martín N, Mercadillo M, <i> et al.</i>: The neglected intrinsic resistome of bacterial pathogens. <i>PLoS One.</i> 2008; <b>3</b>(2): e1619. <a target=xrefwindow id=d20924e1696 href="http://www.ncbi.nlm.nih.gov/pubmed/18286176">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1699 href="https://doi.org/10.1371/journal.pone.0001619">Publisher Full Text </a> | <a target=xrefwindow id=d20924e1703 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2238818">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1102233">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d20924e1716 class=n-a></a>López-Causapé C, Cabot G, Del Barrio-Tofiño E, <i> et al.</i>: The Versatile Mutational Resistome of <i>Pseudomonas aeruginosa</i>. <i>Front Microbiol.</i> 2018; <b>9</b>: 685. <a target=xrefwindow id=d20924e1730 href="http://www.ncbi.nlm.nih.gov/pubmed/29681898">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1734 href="https://doi.org/10.3389/fmicb.2018.00685">Publisher Full Text </a> | <a target=xrefwindow id=d20924e1737 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5897538">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d20924e1747 class=n-a></a>Potron A, Poirel L, Nordmann P: Emerging broad-spectrum resistance in <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i>: Mechanisms and epidemiology. <i>Int J Antimicrob Agents.</i> 2015; <b>45</b>(6): 568–85. <a target=xrefwindow id=d20924e1761 href="http://www.ncbi.nlm.nih.gov/pubmed/25857949">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1765 href="https://doi.org/10.1016/j.ijantimicag.2015.03.001">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d20924e1774 class=n-a></a>Eichenberger EM, Thaden JT: Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria. <i>Antibiotics (Basel).</i> 2019; <b>8</b>(2): pii: E37. <a target=xrefwindow id=d20924e1782 href="http://www.ncbi.nlm.nih.gov/pubmed/30959901">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1785 href="https://doi.org/10.3390/antibiotics8020037">Publisher Full Text </a> | <a target=xrefwindow id=d20924e1788 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6628318">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d20924e1797 class=n-a></a>Pérez A, Gato E, Pérez-Llarena J, <i> et al.</i>: High incidence of MDR and XDR <i>Pseudomonas aeruginosa</i> isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. <i>J Antimicrob Chemother.</i> 2019; <b>74</b>(5): 1244–52. <a target=xrefwindow id=d20924e1811 href="http://www.ncbi.nlm.nih.gov/pubmed/30753505">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1815 href="https://doi.org/10.1093/jac/dkz030">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d20924e1824 class=n-a></a>Del Barrio-Tofiño E, Zamorano L, Cortes-Lara S, <i> et al.</i>: Spanish nationwide survey on <i>Pseudomonas aeruginosa</i> antimicrobial resistance mechanisms and epidemiology. <i>J Antimicrob Chemother.</i> 2019; <b>74</b>(7): 1825–35. <a target=xrefwindow id=d20924e1838 href="http://www.ncbi.nlm.nih.gov/pubmed/30989186">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1842 href="https://doi.org/10.1093/jac/dkz147">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d20924e1851 class=n-a></a>Carb-X Combating Antibiotic Resistant Bacteria. Carb-X, 2019. <a target=xrefwindow id=d20924e1853 href="https://carb-x.org/">Reference Source</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d20924e1862 class=n-a></a>Olaitan AO, Morand S, Rolain JM: Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. <i>Front Microbiol.</i> 2014; <b>5</b>: 643. <a target=xrefwindow id=d20924e1870 href="http://www.ncbi.nlm.nih.gov/pubmed/25505462">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1873 href="https://doi.org/10.3389/fmicb.2014.00643">Publisher Full Text </a> | <a target=xrefwindow id=d20924e1876 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4244539">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727281022"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e1886 class=n-a></a>Jeannot K, Bolard A, Plésiat P: Resistance to polymyxins in Gram-negative organisms. <i>Int J Antimicrob Agents.</i> 2017; <b>49</b>(5): 526–35. <a target=xrefwindow id=d20924e1894 href="http://www.ncbi.nlm.nih.gov/pubmed/28163137">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1897 href="https://doi.org/10.1016/j.ijantimicag.2016.11.029">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727281022">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d20924e1910 class=n-a></a>van Duin D, Bonomo RA: Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. <i>Clin Infect Dis.</i> 2016; <b>63</b>(2): 234–41. <a target=xrefwindow id=d20924e1918 href="http://www.ncbi.nlm.nih.gov/pubmed/27098166">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1921 href="https://doi.org/10.1093/cid/ciw243">Publisher Full Text </a> | <a target=xrefwindow id=d20924e1924 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4928383">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d20924e1933 class=n-a></a>Evans SR, Tran TTT, Hujer AM, <i> et al.</i>: Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against <i>Pseudomonas aeruginosa</i>: PRIMERS IV. <i>Clin Infect Dis.</i> 2019; <b>68</b>(11): 1823–30. <a target=xrefwindow id=d20924e1947 href="http://www.ncbi.nlm.nih.gov/pubmed/30239599">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1951 href="https://doi.org/10.1093/cid/ciy801">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d20924e1960 class=n-a></a>Sader HS, Flamm RK, Carvalhaes CG, <i> et al.</i>: Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. <i>Antimicrob Agents Chemother.</i> 2018; <b>62</b>(12): pii: e01587-18. <a target=xrefwindow id=d20924e1974 href="http://www.ncbi.nlm.nih.gov/pubmed/30224535">PubMed Abstract </a> | <a target=xrefwindow id=d20924e1978 href="https://doi.org/10.1128/AAC.01587-18">Publisher Full Text </a> | <a target=xrefwindow id=d20924e1981 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6256773">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d20924e1990 class=n-a></a>Karlowsky JA, Kazmierczak KM, Bouchillon SK, <i> et al.</i>: <i>In Vitro</i> Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015. <i>Antimicrob Agents Chemother.</i> 2019; <b>63</b>(4): pii: e01814-18. <a target=xrefwindow id=d20924e2008 href="http://www.ncbi.nlm.nih.gov/pubmed/30670424">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2011 href="https://doi.org/10.1128/AAC.01814-18">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2014 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6437529">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d20924e2023 class=n-a></a>Schaumburg F, Bletz S, Mellmann A, <i> et al.</i>: Comparison of methods to analyse susceptibility of German MDR/XDR <i>Pseudomonas aeruginosa</i> to ceftazidime/avibactam. <i>Int J Antimicrob Agents.</i> 2019; <b>54</b>(2): 255–260, pii: S0924-8579(19)30108-6. <a target=xrefwindow id=d20924e2037 href="http://www.ncbi.nlm.nih.gov/pubmed/31071465">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2041 href="https://doi.org/10.1016/j.ijantimicag.2019.05.001">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d20924e2051 class=n-a></a>Zamudio R, Hijazi K, Joshi C, <i> et al.</i>: Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant <i>Pseudomonas aeruginosa</i> from cystic fibrosis patients. <i>Int J Antimicrob Agents.</i> 2019; <b>53</b>(6): 774–80. <a target=xrefwindow id=d20924e2065 href="http://www.ncbi.nlm.nih.gov/pubmed/30831233">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2069 href="https://doi.org/10.1016/j.ijantimicag.2019.02.022">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d20924e2078 class=n-a></a>Poirel L, Ortiz De La Rosa JM, Kieffer N, <i> et al.</i>: Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in <i>Pseudomonas aeruginosa</i>. <i>Antimicrob Agents Chemother.</i> 2019; <b>63</b>(1): pii: e01809-18. <a target=xrefwindow id=d20924e2092 href="http://www.ncbi.nlm.nih.gov/pubmed/30323045">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2096 href="https://doi.org/10.1128/AAC.01809-18">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2099 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6325188">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d20924e2108 class=n-a></a>Jean SS, Gould IM, Lee WS, <i> et al.</i>: New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship. <i>Drugs.</i> 2019; <b>79</b>(7): 705–14. <a target=xrefwindow id=d20924e2119 href="http://www.ncbi.nlm.nih.gov/pubmed/30972660">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2122 href="https://doi.org/10.1007/s40265-019-01112-1">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d20924e2131 class=n-a></a>Horner C, Mushtaq S, Livermore DM, <i> et al.</i>: Potentiation of imipenem by relebactam for <i>Pseudomonas aeruginosa</i> from bacteraemia and respiratory infections. <i>J Antimicrob Chemother.</i> 2019; <b>74</b>(7): 1940–4. <a target=xrefwindow id=d20924e2145 href="http://www.ncbi.nlm.nih.gov/pubmed/31032858">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2149 href="https://doi.org/10.1093/jac/dkz133">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732323316"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e2158 class=n-a></a>Zhanel GG, Lawrence CK, Adam H, <i> et al.</i>: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. <i>Drugs.</i> 2018; <b>78</b>(1): 65–98. <a target=xrefwindow id=d20924e2169 href="http://www.ncbi.nlm.nih.gov/pubmed/29230684">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2172 href="https://doi.org/10.1007/s40265-017-0851-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732323316">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733754733"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e2185 class=n-a></a>Karlowsky JA, Lob SH, Young K, <i> et al.</i>: Activity of imipenem/relebactam against <i>Pseudomonas aeruginosa</i> with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016. <i>J Glob Antimicrob Resist.</i> 2018; <b>15</b>: 140–7. <a target=xrefwindow id=d20924e2199 href="http://www.ncbi.nlm.nih.gov/pubmed/30071354">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2203 href="https://doi.org/10.1016/j.jgar.2018.07.012">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733754733">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d20924e2217 class=n-a></a>Thomson KS, AbdelGhani S, Snyder JW, <i> et al.</i>: Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens. <i>Antibiotics (Basel).</i> 2019; <b>8</b>(1): pii: E32. <a target=xrefwindow id=d20924e2228 href="http://www.ncbi.nlm.nih.gov/pubmed/30909535">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2231 href="https://doi.org/10.3390/antibiotics8010032">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2235 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6466586">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d20924e2244 class=n-a></a>Moya B, Barcelo IM, Bhagwat S, <i> et al.</i>: WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against <i>Pseudomonas aeruginosa</i>, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. <i>Antimicrob Agents Chemother.</i> 2017; <b>61</b>(6): pii: e02529-16. <a target=xrefwindow id=d20924e2258 href="http://www.ncbi.nlm.nih.gov/pubmed/28289035">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2262 href="https://doi.org/10.1128/AAC.02529-16">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2265 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5444176">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d20924e2274 class=n-a></a>Okujava R, Garcia-Alcalde F, Haldimann A, <i> et al.</i>: 1359. Activity of Meropenem/Nacubactam Combination Against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017. <i>Open Forum Infect Dis.</i> 2018; <b>5</b>(Suppl 1): S416. <a target=xrefwindow id=d20924e2285 href="https://doi.org/10.1093/ofid/ofy210.1190">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2288 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6252560">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d20924e2297 class=n-a></a>Daigle D, Hamrick J, Chatwin C, <i> et al.</i>: 1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant <i>K. pneumoniae</i> and <i>P. aeruginosa</i>. <i>Open Forum Infect Dis.</i> 2018; <b>5</b>(Suppl 1): S419–S420. <a target=xrefwindow id=d20924e2315 href="https://doi.org/10.1093/ofid/ofy210.1201">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2318 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6252657">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734998731"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e2327 class=n-a></a>Zhanel GG, Golden AR, Zelenitsky S, <i> et al.</i>: Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs.</i> 2019; <b>79</b>(3): 271–89. <a target=xrefwindow id=d20924e2338 href="http://www.ncbi.nlm.nih.gov/pubmed/30712199">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2341 href="https://doi.org/10.1007/s40265-019-1055-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734998731">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d20924e2354 class=n-a></a>Portsmouth S, van Veenhuyzen D, Echols R, <i> et al.</i>: Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. <i>Lancet Infect Dis.</i> 2018; <b>18</b>(12): 1319–28. <a target=xrefwindow id=d20924e2365 href="http://www.ncbi.nlm.nih.gov/pubmed/30509675">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2368 href="https://doi.org/10.1016/S1473-3099(18)30554-1">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726840977"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e2378 class=n-a></a>Ito A, Nishikawa T, Matsumoto S, <i> et al.</i>: Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against <i>Pseudomonas aeruginosa</i>. <i>Antimicrob Agents Chemother.</i> 2016; <b>60</b>(12): 7396–401. <a target=xrefwindow id=d20924e2392 href="http://www.ncbi.nlm.nih.gov/pubmed/27736756">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2396 href="https://doi.org/10.1128/AAC.01405-16">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2399 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5119021">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726840977">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d20924e2412 class=n-a></a>Ito A, Sato T, Ota M, <i> et al.</i>: <i>In Vitro</i> Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. <i>Antimicrob Agents Chemother.</i> 2018; <b>62</b>(1): pii: e01454-17. <a target=xrefwindow id=d20924e2426 href="http://www.ncbi.nlm.nih.gov/pubmed/29061741">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2430 href="https://doi.org/10.1128/AAC.01454-17">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2433 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5740388">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d20924e2442 class=n-a></a>Hsueh SC, Lee YJ, Huang YT, <i> et al.</i>: <i>In vitro</i> activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i>, and <i>Stenotrophomonas maltophilia</i>, all associated with bloodstream infections in Taiwan. <i>J Antimicrob Chemother.</i> 2019; <b>74</b>(2): 380–6. <a target=xrefwindow id=d20924e2466 href="http://www.ncbi.nlm.nih.gov/pubmed/30357343">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2469 href="https://doi.org/10.1093/jac/dky425">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d20924e2478 class=n-a></a>Ito A, Nishikawa T, Ota M, <i> et al.</i>: Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of <i>Pseudomonas aeruginosa</i> and <i>Enterobacter cloacae</i>. <i>J Antimicrob Chemother.</i> 2019; <b>74</b>(2): 539. <a target=xrefwindow id=d20924e2496 href="http://www.ncbi.nlm.nih.gov/pubmed/30445536">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2499 href="https://doi.org/10.1093/jac/dky482">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2502 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6338063">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d20924e2511 class=n-a></a>Jacobs MR, Abdelhamed AM, Good CE, <i> et al.</i>: ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases. <i>Antimicrob Agents Chemother.</i> 2018; <b>63</b>(1): pii: e01801-18. <a target=xrefwindow id=d20924e2522 href="http://www.ncbi.nlm.nih.gov/pubmed/30323050">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2525 href="https://doi.org/10.1128/AAC.01801-18">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2529 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6325197">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d20924e2538 class=n-a></a>Kazmierczak KM, Tsuji M, Wise MG, <i> et al.</i>: <i>In vitro</i> activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). <i>Int J Antimicrob Agents.</i> 2019; <b>53</b>(2): 177–84. <a target=xrefwindow id=d20924e2552 href="http://www.ncbi.nlm.nih.gov/pubmed/30395986">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2556 href="https://doi.org/10.1016/j.ijantimicag.2018.10.007">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d20924e2566 class=n-a></a>Voulgaris GL, Voulgari ML, Falagas ME: Developments on antibiotics for multidrug resistant bacterial Gram-negative infections. <i>Expert Rev Anti Infect Ther.</i> 2019; <b>17</b>(6): 387–401. <a target=xrefwindow id=d20924e2574 href="http://www.ncbi.nlm.nih.gov/pubmed/31006284">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2577 href="https://doi.org/10.1080/14787210.2019.1610392">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d20924e2586 class=n-a></a>Stubbings W, Leow P, Yong GC, <i> et al.</i>: <i>In vitro</i> spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions. <i>Antimicrob Agents Chemother.</i> 2011; <b>55</b>(9): 4394–7. <a target=xrefwindow id=d20924e2600 href="http://www.ncbi.nlm.nih.gov/pubmed/21709094">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2604 href="https://doi.org/10.1128/AAC.00833-10">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2607 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3165343">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d20924e2616 class=n-a></a>Ocheretyaner ER, Park TE: Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and <i>Pseudomonas aeruginosa</i>. <i>Expert Rev Anti Infect Ther.</i> 2018; <b>16</b>(7): 523–30. <a target=xrefwindow id=d20924e2630 href="http://www.ncbi.nlm.nih.gov/pubmed/29911455">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2634 href="https://doi.org/10.1080/14787210.2018.1489721">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d20924e2643 class=n-a></a>Tulkens PM, Van Bambeke F, Zinner SH: Profile of a Novel Anionic Fluoroquinolone-Delafloxacin. <i>Clin Infect Dis.</i> 2019; <b>68</b>(Supplement_3): S213–S222. <a target=xrefwindow id=d20924e2651 href="http://www.ncbi.nlm.nih.gov/pubmed/30957164">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2654 href="https://doi.org/10.1093/cid/ciy1079">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2657 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6452001">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732542926"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e2666 class=n-a></a>Andolina G, Bencze LC, Zerbe K, <i> et al.</i>: A Peptidomimetic Antibiotic Interacts with the Periplasmic Domain of LptD from <i>Pseudomonas aeruginosa</i>. <i>ACS Chem Biol.</i> 2018; <b>13</b>(3): 666–75. <a target=xrefwindow id=d20924e2680 href="http://www.ncbi.nlm.nih.gov/pubmed/29359918">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2684 href="https://doi.org/10.1021/acschembio.7b00822">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732542926">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d20924e2697 class=n-a></a>Sader HS, Dale GE, Rhomberg PR, <i> et al.</i>: Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of <i>Pseudomonas aeruginosa</i> from the United States, Europe, and China. <i>Antimicrob Agents Chemother.</i> 2018; <b>62</b>(7): pii: e00311-18. <a target=xrefwindow id=d20924e2711 href="http://www.ncbi.nlm.nih.gov/pubmed/29686157">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2715 href="https://doi.org/10.1128/AAC.00311-18">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2718 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6021639">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733450378"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e2728 class=n-a></a>Sader HS, Flamm RK, Dale GE, <i> et al.</i>: Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR <i>Pseudomonas aeruginosa</i>. <i>J Antimicrob Chemother.</i> 2018; <b>73</b>(9): 2400–4. <a target=xrefwindow id=d20924e2742 href="http://www.ncbi.nlm.nih.gov/pubmed/29901750">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2746 href="https://doi.org/10.1093/jac/dky227">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733450378">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d20924e2759 class=n-a></a>Gorr SU, Flory CM, Schumacher RJ: <i>In vivo</i> activity and low toxicity of the second-generation antimicrobial peptide DGL13K. <i>PLoS One.</i> 2019; <b>14</b>(5): e0216669. <a target=xrefwindow id=d20924e2770 href="http://www.ncbi.nlm.nih.gov/pubmed/31071184">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2773 href="https://doi.org/10.1371/journal.pone.0216669">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2777 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6508730">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d20924e2786 class=n-a></a>Yasir M, Dutta D, Willcox MDP: Comparative mode of action of the antimicrobial peptide melimine and its derivative Mel4 against <i>Pseudomonas aeruginosa</i>. <i>Sci Rep.</i> 2019; <b>9</b>(1): 7063. <a target=xrefwindow id=d20924e2797 href="http://www.ncbi.nlm.nih.gov/pubmed/31068610">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2800 href="https://doi.org/10.1038/s41598-019-42440-2">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2804 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6506473">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d20924e2813 class=n-a></a>Romoli O, Mukherjee S, Mohid SA, <i> et al.</i>: Enhanced Silkworm Cecropin B Antimicrobial Activity against <i>Pseudomonas aeruginosa</i> from Single Amino Acid Variation. <i>ACS Infect Dis.</i> 2019; <b>5</b>(7): 1200–13. <a target=xrefwindow id=d20924e2827 href="http://www.ncbi.nlm.nih.gov/pubmed/31045339">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2831 href="https://doi.org/10.1021/acsinfecdis.9b00042">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d20924e2840 class=n-a></a>Molchanova N, Wang H, Hansen PR, <i> et al.</i>: Antimicrobial Activity of α-Peptide/β-Peptoid Lysine-Based Peptidomimetics Against Colistin-Resistant <i>Pseudomonas aeruginosa</i> Isolated From Cystic Fibrosis Patients. <i>Front Microbiol.</i> 2019; <b>10</b>: 275. <a target=xrefwindow id=d20924e2854 href="http://www.ncbi.nlm.nih.gov/pubmed/30842761">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2858 href="https://doi.org/10.3389/fmicb.2019.00275">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2861 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6391360">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d20924e2870 class=n-a></a>Cândido ES, Cardoso MH, Chan LY, <i> et al.</i>: Short Cationic Peptide Derived from Archaea with Dual Antibacterial Properties and Anti-Infective Potential. <i>ACS Infect. Dis.</i> 2019; <b>5</b>(7): 1081–1086. <a target=xrefwindow id=d20924e2881 href="http://www.ncbi.nlm.nih.gov/pubmed/31016969">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2884 href="https://doi.org/10.1021/acsinfecdis.9b00073">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d20924e2894 class=n-a></a>Kang HK, Seo CH, Luchian T, <i> et al.</i>: Pse-T2, an Antimicrobial Peptide with High-Level, Broad-Spectrum Antimicrobial Potency and Skin Biocompatibility against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection. <i>Antimicrob Agents Chemother.</i> 2018; <b>62</b>(12): pii: e01493-18. <a target=xrefwindow id=d20924e2908 href="http://www.ncbi.nlm.nih.gov/pubmed/30323036">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2912 href="https://doi.org/10.1128/AAC.01493-18">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2915 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6256760">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d20924e2924 class=n-a></a>Beaudoin T, Stone TA, Glibowicka M, <i> et al.</i>: Activity of a novel antimicrobial peptide against <i>Pseudomonas aeruginosa</i> biofilms. <i>Sci Rep.</i> 2018; <b>8</b>(1): 14728. <a target=xrefwindow id=d20924e2938 href="http://www.ncbi.nlm.nih.gov/pubmed/30283025">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2942 href="https://doi.org/10.1038/s41598-018-33016-7">Publisher Full Text </a> | <a target=xrefwindow id=d20924e2945 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6170476">Free Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d20924e2954 class=n-a></a>Akbari R, Hakemi Vala M, Hashemi A, <i> et al.</i>: Action mechanism of melittin-derived antimicrobial peptides, MDP1 and MDP2, de novo designed against multidrug resistant bacteria. <i>Amino Acids.</i> 2018; <b>50</b>(9): 1231–43. <a target=xrefwindow id=d20924e2965 href="http://www.ncbi.nlm.nih.gov/pubmed/29905903">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2968 href="https://doi.org/10.1007/s00726-018-2596-5">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718730957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e2977 class=n-a></a>Ramsey BW, Dorkin HL, Eisenberg JD, <i> et al.</i>: Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis. <i>N Engl J Med.</i> 1993; <b>328</b>(24): 1740–6. <a target=xrefwindow id=d20924e2988 href="http://www.ncbi.nlm.nih.gov/pubmed/8497284">PubMed Abstract </a> | <a target=xrefwindow id=d20924e2991 href="https://doi.org/10.1056/NEJM199306173282403">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718730957">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d20924e3004 class=n-a></a>Shteinberg M, Elborn JS: Use of inhaled tobramycin in cystic fibrosis. <i>Adv Ther.</i> 2015; <b>32</b>(1): 1–9. <a target=xrefwindow id=d20924e3012 href="http://www.ncbi.nlm.nih.gov/pubmed/25620537">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3015 href="https://doi.org/10.1007/s12325-015-0179-3">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d20924e3024 class=n-a></a>Vardakas KZ, Voulgaris GL, Samonis G, <i> et al.</i>: Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: A systematic review and meta-analysis. <i>Int J Antimicrob Agents.</i> 2018; <b>51</b>(1): 1–9. <a target=xrefwindow id=d20924e3035 href="http://www.ncbi.nlm.nih.gov/pubmed/28669836">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3038 href="https://doi.org/10.1016/j.ijantimicag.2017.05.016">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d20924e3048 class=n-a></a>Koerner-Rettberg C, Ballmann M: Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: An evidence-based review of its place in therapy. <i>Core Evid.</i> 2014; <b>9</b>: 99–112. <a target=xrefwindow id=d20924e3056 href="http://www.ncbi.nlm.nih.gov/pubmed/25278817">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3059 href="https://doi.org/10.2147/CE.S64980">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3062 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4178503">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d20924e3071 class=n-a></a>Conole D, Keating GM: Colistimethate sodium dry powder for inhalation: A review of its use in the treatment of chronic <i>Pseudomonas aeruginosa</i> infection in patients with cystic fibrosis. <i>Drugs.</i> 2014; <b>74</b>(3): 377–87. <a target=xrefwindow id=d20924e3082 href="http://www.ncbi.nlm.nih.gov/pubmed/24510624">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3085 href="https://doi.org/10.1007/s40265-014-0181-0">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d20924e3094 class=n-a></a>McCoy KS, Quittner AL, Oermann CM, <i> et al.</i>: Inhaled Aztreonam Lysine for Chronic Airway <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis. <i>Am J Respir Crit Care Med.</i> 2008; <b>178</b>(9): 921–8. <a target=xrefwindow id=d20924e3108 href="http://www.ncbi.nlm.nih.gov/pubmed/18658109">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3112 href="https://doi.org/10.1164/rccm.200712-1804OC">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3115 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2577727">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d20924e3124 class=n-a></a>Oermann CM, Retsch-Bogart GZ, Quittner AL, <i> et al.</i>: An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. <i>Pediatr Pulmonol.</i> 2010; <b>45</b>(11): 1121–34. <a target=xrefwindow id=d20924e3135 href="http://www.ncbi.nlm.nih.gov/pubmed/20672296">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3138 href="https://doi.org/10.1002/ppul.21301">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3142 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3867945">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d20924e3151 class=n-a></a>Elson EC, Mermis J, Polineni D, <i> et al.</i>: Aztreonam Lysine Inhalation Solution in Cystic Fibrosis. <i>Clin Med Insights Circ Respir Pulm Med.</i> 2019; <b>13</b>: 1179548419842822. <a target=xrefwindow id=d20924e3162 href="http://www.ncbi.nlm.nih.gov/pubmed/31019373">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3165 href="https://doi.org/10.1177/1179548419842822">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3169 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6463232">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d20924e3178 class=n-a></a>Ehsan Z, Clancy JP: Management of <i>Pseudomonas aeruginosa</i> infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. <i>Future Microbiol.</i> 2015; <b>10</b>(12): 1901–12. <a target=xrefwindow id=d20924e3189 href="http://www.ncbi.nlm.nih.gov/pubmed/26573178">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3192 href="https://doi.org/10.2217/fmb.15.117">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3196 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4944396">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732571638"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e3206 class=n-a></a>Aksamit T, de Soyza A, Bandel TJ, <i> et al.</i>: RESPIRE 2: A phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. <i>Eur Respir J.</i> 2018; <b>51</b>(1): pii: 1702053. <a target=xrefwindow id=d20924e3217 href="http://www.ncbi.nlm.nih.gov/pubmed/29371384">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3220 href="https://doi.org/10.1183/13993003.02053-2017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732571638">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732571639"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e3233 class=n-a></a>de Soyza A, Aksamit T, Bandel TJ, <i> et al.</i>: RESPIRE 1: A phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. <i>Eur Respir J.</i> 2018; <b>51</b>(1): pii: 1702052. <a target=xrefwindow id=d20924e3244 href="http://www.ncbi.nlm.nih.gov/pubmed/29371383">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3247 href="https://doi.org/10.1183/13993003.02052-2017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732571639">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d20924e3260 class=n-a></a>VanDevanter DR, Gonda I, Dahms J, <i> et al.</i>: Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic <i>Pseudomonas aeruginosa</i> lung infection. <i>Clin Microbiol Infect.</i> 2019; pii: S1198-743X(19)30194-6. <a target=xrefwindow id=d20924e3271 href="http://www.ncbi.nlm.nih.gov/pubmed/31035017">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3274 href="https://doi.org/10.1016/j.cmi.2019.04.017">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d20924e3283 class=n-a></a>Haworth CS, Bilton D, Chalmers JD, <i> et al.</i>: Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with <i>Pseudomonas aeruginosa</i> (ORBIT-3 and ORBIT-4): Two phase 3, randomised controlled trials. <i>Lancet Respir Med.</i> 2019; <b>7</b>(3): 213–26. <a target=xrefwindow id=d20924e3297 href="http://www.ncbi.nlm.nih.gov/pubmed/30658914">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3301 href="https://doi.org/10.1016/S2213-2600(18)30427-2">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d20924e3310 class=n-a></a>Derbali RM, Aoun V, Moussa G, <i> et al.</i>: Tailored Nanocarriers for the Pulmonary Delivery of Levofloxacin against <i>Pseudomonas aeruginosa</i>: A Comparative Study. <i>Mol Pharm.</i> 2019; <b>16</b>(5): 1906–16. <a target=xrefwindow id=d20924e3324 href="http://www.ncbi.nlm.nih.gov/pubmed/30900903">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3328 href="https://doi.org/10.1021/acs.molpharmaceut.8b01256">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d20924e3337 class=n-a></a>Clancy JP, Dupont L, Konstan MW, <i> et al.</i>: Phase II studies of nebulised Arikace in CF patients with <i>Pseudomonas aeruginosa</i> infection. <i>Thorax.</i> 2013; <b>68</b>(9): 818–25. <a target=xrefwindow id=d20924e3351 href="http://www.ncbi.nlm.nih.gov/pubmed/23749840">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3355 href="https://doi.org/10.1136/thoraxjnl-2012-202230">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3358 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3756431">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734461297"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e3368 class=n-a></a>Chotirmall SH, Chalmers JD: RESPIRE: breathing new life into bronchiectasis. <i>Eur Respir J.</i> 2018; <b>51</b>(1): pii: 1702444. <a target=xrefwindow id=d20924e3376 href="http://www.ncbi.nlm.nih.gov/pubmed/29371393">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3379 href="https://doi.org/10.1183/13993003.02444-2017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734461297">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1109131"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e3392 class=n-a></a>Pamp SJ, Gjermansen M, Johansen HK, <i> et al.</i>: Tolerance to the antimicrobial peptide colistin in <i>Pseudomonas aeruginosa</i> biofilms is linked to metabolically active cells, and depends on the <i>pmr</i> and <i>mexAB-oprM</i> genes. <i>Mol Microbiol.</i> 2008; <b>68</b>(1): 223–40. <a target=xrefwindow id=d20924e3413 href="http://www.ncbi.nlm.nih.gov/pubmed/18312276">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3416 href="https://doi.org/10.1111/j.1365-2958.2008.06152.x">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1109131">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d20924e3429 class=n-a></a>Herrmann G, Yang L, Wu H, <i> et al.</i>: Colistin-Tobramycin Combinations Are Superior to Monotherapy Concerning the Killing of Biofilm <i>Pseudomonas aeruginosa</i>. <i>J Infect Dis.</i> 2010; <b>202</b>(10): 1585–92. <a target=xrefwindow id=d20924e3443 href="http://www.ncbi.nlm.nih.gov/pubmed/20942647">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3447 href="https://doi.org/10.1086/656788">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d20924e3456 class=n-a></a>Riethmüller J, Herrmann G, Graepler-Mainka U, <i> et al.</i>: Sequential Inhalational Tobramycin-Colistin-Combination in CF-Patients with Chronic <i>P. Aeruginosa</i> Colonization - an Observational Study. <i>Cell Physiol Biochem.</i> 2016; <b>39</b>(3): 1141–51. <a target=xrefwindow id=d20924e3470 href="http://www.ncbi.nlm.nih.gov/pubmed/27576543">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3474 href="https://doi.org/10.1159/000447821">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d20924e3483 class=n-a></a>Rojo-Molinero E, Macià MD, Rubio R, <i> et al.</i>: Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating <i>Pseudomonas aeruginosa</i> Chronic Respiratory Infections. <i>Antimicrob Agents Chemother.</i> 2016; <b>60</b>(5): 2912–22. <a target=xrefwindow id=d20924e3497 href="http://www.ncbi.nlm.nih.gov/pubmed/26926631">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3501 href="https://doi.org/10.1128/AAC.00196-16">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3504 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4862541">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d20924e3513 class=n-a></a>Tschudin-Sutter S, Fosse N, Frei R, <i> et al.</i>: Combination therapy for treatment of <i>Pseudomonas aeruginosa</i> bloodstream infections. <i>PLoS One.</i> 2018; <b>13</b>(9): e0203295. <a target=xrefwindow id=d20924e3527 href="http://www.ncbi.nlm.nih.gov/pubmed/30235247">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3531 href="https://doi.org/10.1371/journal.pone.0203295">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3534 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6147480">Free Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d20924e3544 class=n-a></a>Jiao Y, Moya B, Chen MJ, <i> et al.</i>: Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. <i>Antimicrob Agents Chemother.</i> 2019; <b>63</b>(7): pii: e00425-19. <a target=xrefwindow id=d20924e3555 href="http://www.ncbi.nlm.nih.gov/pubmed/30988147">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3558 href="https://doi.org/10.1128/AAC.00425-19">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3562 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6591590">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718601564"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e3571 class=n-a></a>Vaara M, Vaara T: Sensitization of Gram-negative bacteria to antibiotics and complement by a nontoxic oligopeptide. <i>Nature.</i> 1983; <b>303</b>(5917): 526–8. <a target=xrefwindow id=d20924e3579 href="http://www.ncbi.nlm.nih.gov/pubmed/6406904">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3582 href="https://doi.org/10.1038/303526a0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718601564">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d20924e3595 class=n-a></a>Kubesch P, Wehsling M, Tümmler B: Membrane permeability of <i>Pseudomonas aeruginosa</i> to 4-quinolones. <i>Zentralbl Bakteriol Mikrobiol Hyg A.</i> 1987; <b>265</b>(1–2): 197–202. <a target=xrefwindow id=d20924e3606 href="http://www.ncbi.nlm.nih.gov/pubmed/3118593">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3609 href="https://doi.org/10.1016/S0176-6724(87)80166-9">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d20924e3618 class=n-a></a>Stokes JM, MacNair CR, Ilyas B, <i> et al.</i>: Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance. <i>Nat Microbiol.</i> 2017; <b>2</b>: 17028. <a target=xrefwindow id=d20924e3629 href="http://www.ncbi.nlm.nih.gov/pubmed/28263303">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3632 href="https://doi.org/10.1038/nmicrobiol.2017.28">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3636 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5360458">Free Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d20924e3645 class=n-a></a>Corbett D, Wise A, Langley T, <i> et al.</i>: Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741. <i>Antimicrob Agents Chemother.</i> 2017; <b>61</b>(8): pii: e00200-17. <a target=xrefwindow id=d20924e3656 href="http://www.ncbi.nlm.nih.gov/pubmed/28533232">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3659 href="https://doi.org/10.1128/AAC.00200-17">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3663 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5527571">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734865088"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e3672 class=n-a></a>Vaara M: Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics. <i>Molecules.</i> 2019; <b>24</b>(2): pii: E249. <a target=xrefwindow id=d20924e3680 href="http://www.ncbi.nlm.nih.gov/pubmed/30641878">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3683 href="https://doi.org/10.3390/molecules24020249">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3686 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6359160">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734865088">F1000 Recommendation</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734414225"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e3700 class=n-a></a>Schütz C, Empting M: Targeting the <i>Pseudomonas</i> quinolone signal quorum sensing system for the discovery of novel anti-infective pathoblockers. <i>Beilstein J Org Chem.</i> 2018; <b>14</b>: 2627–45. <a target=xrefwindow id=d20924e3711 href="http://www.ncbi.nlm.nih.gov/pubmed/30410625">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3714 href="https://doi.org/10.3762/bjoc.14.241">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3718 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6204780">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734414225">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d20924e3731 class=n-a></a>Soheili V, Tajani AS, Ghodsi R, <i> et al.</i>: Anti-PqsR compounds as next-generation antibacterial agents against <i>Pseudomonas aeruginosa</i>: A review. <i>Eur J Med Chem.</i> 2019; <b>172</b>: 26–35. <a target=xrefwindow id=d20924e3745 href="http://www.ncbi.nlm.nih.gov/pubmed/30939351">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3749 href="https://doi.org/10.1016/j.ejmech.2019.03.049">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d20924e3758 class=n-a></a>Welsh MA, Blackwell HE: Chemical probes of quorum sensing: from compound development to biological discovery. <i>FEMS Microbiol Rev.</i> 2016; <b>40</b>(5): 774–94. <a target=xrefwindow id=d20924e3766 href="http://www.ncbi.nlm.nih.gov/pubmed/27268906">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3769 href="https://doi.org/10.1093/femsre/fuw009">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3772 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5007280">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d20924e3781 class=n-a></a>Defoirdt T: Quorum-Sensing Systems as Targets for Antivirulence Therapy. <i>Trends Microbiol.</i> 2018; <b>26</b>(4): 313–28. <a target=xrefwindow id=d20924e3789 href="http://www.ncbi.nlm.nih.gov/pubmed/29132819">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3792 href="https://doi.org/10.1016/j.tim.2017.10.005">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736290650"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e3801 class=n-a></a>Kudoh S, Uetake T, Hagiwara K, <i> et al.</i>: [Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis]. <i>Nihon Kyobu Shikkan Gakkai Zasshi.</i> 1987; <b>25</b>(6): 632–42. <a target=xrefwindow id=d20924e3812 href="http://www.ncbi.nlm.nih.gov/pubmed/3682440">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3815 href="https://doi.org/10.11389/jjrs1963.25.632">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736290650">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d20924e3828 class=n-a></a>Tateda K, Comte R, Pechere JC, <i> et al.</i>: Azithromycin inhibits quorum sensing in <i>Pseudomonas aeruginosa</i>. <i>Antimicrob Agents Chemother.</i> 2001; <b>45</b>(6): 1930–3. <a target=xrefwindow id=d20924e3842 href="http://www.ncbi.nlm.nih.gov/pubmed/11353657">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3846 href="https://doi.org/10.1128/AAC.45.6.1930-1933.2001">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3849 href="http://www.ncbi.nlm.nih.gov/pmc/articles/90577">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/721954155"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e3859 class=n-a></a>van Delden C, Köhler T, Brunner-Ferber F, <i> et al.</i>: Azithromycin to prevent <i>Pseudomonas aeruginosa</i> ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. <i>Intensive Care Med.</i> 2012; <b>38</b>(7): 1118–25. <a target=xrefwindow id=d20924e3873 href="http://www.ncbi.nlm.nih.gov/pubmed/22527075">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3877 href="https://doi.org/10.1007/s00134-012-2559-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/721954155">F1000 Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725822945"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e3890 class=n-a></a>Kaneko Y, Thoendel M, Olakanmi O, <i> et al.</i>: The transition metal gallium disrupts <i>Pseudomonas aeruginosa</i> iron metabolism and has antimicrobial and antibiofilm activity. <i>J Clin Invest.</i> 2007; <b>117</b>(4): 877–88. <a target=xrefwindow id=d20924e3904 href="http://www.ncbi.nlm.nih.gov/pubmed/17364024">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3908 href="https://doi.org/10.1172/JCI30783">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3911 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1810576">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725822945">F1000 Recommendation</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d20924e3924 class=n-a></a>DeLeon K, Balldin F, Watters C, <i> et al.</i>: Gallium maltolate treatment eradicates <i>Pseudomonas aeruginosa</i> infection in thermally injured mice. <i>Antimicrob Agents Chemother.</i> 2009; <b>53</b>(4): 1331–7. <a target=xrefwindow id=d20924e3938 href="http://www.ncbi.nlm.nih.gov/pubmed/19188381">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3942 href="https://doi.org/10.1128/AAC.01330-08">Publisher Full Text </a> | <a target=xrefwindow id=d20924e3945 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2663094">Free Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d20924e3954 class=n-a></a>Yeterian E, Martin LW, Lamont IL, <i> et al.</i>: An efflux pump is required for siderophore recycling by <i>Pseudomonas aeruginosa</i>. <i>Environ Microbiol Rep.</i> 2010; <b>2</b>(3): 412–8. <a target=xrefwindow id=d20924e3968 href="http://www.ncbi.nlm.nih.gov/pubmed/23766114">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3972 href="https://doi.org/10.1111/j.1758-2229.2009.00115.x">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d20924e3981 class=n-a></a>Halwani M, Yebio B, Suntres ZE, <i> et al.</i>: Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against <i>Pseudomonas aeruginosa</i>. <i>J Antimicrob Chemother.</i> 2008; <b>62</b>(6): 1291–7. <a target=xrefwindow id=d20924e3995 href="http://www.ncbi.nlm.nih.gov/pubmed/18931388">PubMed Abstract </a> | <a target=xrefwindow id=d20924e3999 href="https://doi.org/10.1093/jac/dkn422">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734074887"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e4008 class=n-a></a>Goss CH, Kaneko Y, Khuu L, <i> et al.</i>: Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections. <i>Sci Transl Med.</i> 2018; <b>10</b>(460): pii: eaat7520. <a target=xrefwindow id=d20924e4019 href="http://www.ncbi.nlm.nih.gov/pubmed/30257953">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4022 href="https://doi.org/10.1126/scitranslmed.aat7520">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4026 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6637966">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734074887">F1000 Recommendation</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d20924e4040 class=n-a></a>Bowlin NO, Williams JD, Knoten CA, <i> et al.</i>: Mutations in the <i>Pseudomonas aeruginosa</i> needle protein gene <i>pscF</i> confer resistance to phenoxyacetamide inhibitors of the type III secretion system. <i>Antimicrob Agents Chemother.</i> 2014; <b>58</b>(4): 2211–20. <a target=xrefwindow id=d20924e4058 href="http://www.ncbi.nlm.nih.gov/pubmed/24468789">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4061 href="https://doi.org/10.1128/AAC.02795-13">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4064 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4023729">Free Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d20924e4073 class=n-a></a>Berube BJ, Murphy KR, Torhan MC, <i> et al.</i>: Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of <i>Pseudomonas aeruginosa</i> Infection. <i>Antimicrob Agents Chemother.</i> 2017; <b>61</b>(11): pii: e01202-17. <a target=xrefwindow id=d20924e4087 href="http://www.ncbi.nlm.nih.gov/pubmed/28807906">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4091 href="https://doi.org/10.1128/AAC.01202-17">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4094 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5655109">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733748835"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e4103 class=n-a></a>Frank DW, Vallis A, Wiener-Kronish JP, <i> et al.</i>: Generation and characterization of a protective monoclonal antibody to <i>Pseudomonas aeruginosa</i> PcrV. <i>J Infect Dis.</i> 2002; <b>186</b>(1): 64–73. <a target=xrefwindow id=d20924e4117 href="http://www.ncbi.nlm.nih.gov/pubmed/12089663">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4121 href="https://doi.org/10.1086/341069">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733748835">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732393338"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e4134 class=n-a></a>Jain R, Beckett VV, Konstan MW, <i> et al.</i>: KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with <i>Pseudomonas aeruginosa</i>. <i>J Cyst Fibros.</i> 2018; <b>17</b>(4): 484–91. <a target=xrefwindow id=d20924e4148 href="http://www.ncbi.nlm.nih.gov/pubmed/29292092">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4152 href="https://doi.org/10.1016/j.jcf.2017.12.006">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732393338">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d20924e4165 class=n-a></a>Tabor DE, Oganesyan V, Keller AE, <i> et al.</i>: <i>Pseudomonas aeruginosa</i> PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates. <i>J Infect Dis.</i> 2018; <b>218</b>(12): 1983–94. <a target=xrefwindow id=d20924e4179 href="http://www.ncbi.nlm.nih.gov/pubmed/30016475">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4183 href="https://doi.org/10.1093/infdis/jiy438">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727577859"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e4192 class=n-a></a>Thanabalasuriar A, Surewaard BG, Willson ME, <i> et al.</i>: Bispecific antibody targets multiple <i>Pseudomonas aeruginosa</i> evasion mechanisms in the lung vasculature. <i>J Clin Invest.</i> 2017; <b>127</b>(6): 2249–61. <a target=xrefwindow id=d20924e4206 href="http://www.ncbi.nlm.nih.gov/pubmed/28463232">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4210 href="https://doi.org/10.1172/JCI89652">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4213 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5451222">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727577859">F1000 Recommendation</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d20924e4227 class=n-a></a>Ali SO, Yu XQ, Robbie GJ, <i> et al.</i>: Phase 1 study of MEDI3902, an investigational anti-<i>Pseudomonas aeruginosa</i> PcrV and Psl bispecific human monoclonal antibody, in healthy adults. <i>Clin Microbiol Infect.</i> 2019; <b>25</b>(5): 629.e1–629.e6. <a target=xrefwindow id=d20924e4241 href="http://www.ncbi.nlm.nih.gov/pubmed/30107283">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4245 href="https://doi.org/10.1016/j.cmi.2018.08.004">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d20924e4254 class=n-a></a>Tran TT, Yu H, Vidaillac C, <i> et al.</i>: An evaluation of inhaled antibiotic liposome versus antibiotic nanoplex in controlling infection in bronchiectasis. <i>Int J Pharm.</i> 2019; <b>559</b>: 382–92. <a target=xrefwindow id=d20924e4265 href="http://www.ncbi.nlm.nih.gov/pubmed/30731256">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4268 href="https://doi.org/10.1016/j.ijpharm.2019.01.062">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d20924e4277 class=n-a></a>Tran TT, Vidaillac C, Yu H, <i> et al.</i>: A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior <i>ex vivo</i> mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart. <i>Int J Pharm.</i> 2018; <b>547</b>(1–2): 368–76. <a target=xrefwindow id=d20924e4291 href="http://www.ncbi.nlm.nih.gov/pubmed/29886096">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4295 href="https://doi.org/10.1016/j.ijpharm.2018.06.017">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d20924e4304 class=n-a></a>Wang S, Yu S, Lin Y, <i> et al.</i>: Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced <i>In Vitro</i> Antimicrobial Activities against Multidrug Resistant <i>Pseudomonas aeruginosa</i>. <i>Pharm Res.</i> 2018; <b>35</b>(10): 187. <a target=xrefwindow id=d20924e4322 href="http://www.ncbi.nlm.nih.gov/pubmed/30094660">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4325 href="https://doi.org/10.1007/s11095-018-2464-8">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4328 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6122860">Free Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d20924e4337 class=n-a></a>Zahra MJ, Hamed H, Mohammad RY, <i> et al.</i>: Evaluation and study of antimicrobial activity of nanoliposomal meropenem against <i>Pseudomonas aeruginosa</i> isolates. <i>Artif Cells Nanomed Biotechnol.</i> 2017; <b>45</b>(5): 975–80. <a target=xrefwindow id=d20924e4351 href="http://www.ncbi.nlm.nih.gov/pubmed/27322561">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4355 href="https://doi.org/10.1080/21691401.2016.1198362">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d20924e4364 class=n-a></a>Dai X, Zhao Y, Yu Y, <i> et al.</i>: All-in-one NIR-activated nanoplatforms for enhanced bacterial biofilm eradication. <i>Nanoscale.</i> 2018; <b>10</b>(39): 18520–30. <a target=xrefwindow id=d20924e4375 href="http://www.ncbi.nlm.nih.gov/pubmed/30211421">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4378 href="https://doi.org/10.1039/c8nr04748k">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d20924e4388 class=n-a></a>Bahamondez-Canas TF, Ferrati S, Moraga-Espinoza DF, <i> et al.</i>: Development, Characterization, and <i>In Vitro</i> Testing of Co-Delivered Antimicrobial Dry Powder Formulation for the Treatment of <i>Pseudomonas aeruginosa</i> Biofilms. <i>J Pharm Sci.</i> 2018; <b>107</b>(8): 2172–8. <a target=xrefwindow id=d20924e4406 href="http://www.ncbi.nlm.nih.gov/pubmed/29698726">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4409 href="https://doi.org/10.1016/j.xphs.2018.04.015">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d20924e4418 class=n-a></a>Alhariri M, Majrashi MA, Bahkali AH, <i> et al.</i>: Efficacy of neutral and negatively charged liposome-loaded gentamicin on planktonic bacteria and biofilm communities. <i>Int J Nanomedicine.</i> 2017; <b>12</b>: 6949–61. <a target=xrefwindow id=d20924e4429 href="http://www.ncbi.nlm.nih.gov/pubmed/29075113">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4432 href="https://doi.org/10.2147/IJN.S141709">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4436 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5609801">Free Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d20924e4445 class=n-a></a>Hill M, Cunningham RN, Hathout RM, <i> et al.</i>: Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT. <i>J Funct Biomater.</i> 2019; <b>10</b>(2): pii: E26. <a target=xrefwindow id=d20924e4456 href="http://www.ncbi.nlm.nih.gov/pubmed/31200522">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4459 href="https://doi.org/10.3390/jfb10020026">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4463 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6617385">Free Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d20924e4472 class=n-a></a>Shaaban MI, Shaker MA, Mady FM: Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates. <i>J Nanobiotechnology.</i> 2017; <b>15</b>(1): 29. <a target=xrefwindow id=d20924e4480 href="http://www.ncbi.nlm.nih.gov/pubmed/28399890">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4483 href="https://doi.org/10.1186/s12951-017-0262-9">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4486 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5387208">Free Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d20924e4495 class=n-a></a>Li R, Yuan X, Wei J, <i> et al.</i>: Synthesis and Evaluation of a Chitosan Oligosaccharide-Streptomycin Conjugate against <i>Pseudomonas aeruginosa</i> Biofilms. <i>Mar Drugs.</i> 2019; <b>17</b>(1): pii: E43. <a target=xrefwindow id=d20924e4509 href="http://www.ncbi.nlm.nih.gov/pubmed/30634609">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4513 href="https://doi.org/10.3390/md17010043">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4516 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6356912">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d20924e4525 class=n-a></a>Pushparaj Selvadoss P, Nellore J, Balaraman Ravindrran M, <i> et al.</i>: Enhancement of antimicrobial activity by liposomal oleic acid-loaded antibiotics for the treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i>. <i>Artif Cells Nanomed Biotechnol.</i> 2018; <b>46</b>(2): 268–73. <a target=xrefwindow id=d20924e4539 href="http://www.ncbi.nlm.nih.gov/pubmed/28362119">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4543 href="https://doi.org/10.1080/21691401.2017.1307209">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d20924e4553 class=n-a></a>Severino P, Silveira EF, Loureiro K, <i> et al.</i>: Antimicrobial activity of polymyxin-loaded solid lipid nanoparticles (PLX-SLN): Characterization of physicochemical properties and <i>in vitro</i> efficacy. <i>Eur J Pharm Sci.</i> 2017; <b>106</b>: 177–84. <a target=xrefwindow id=d20924e4567 href="http://www.ncbi.nlm.nih.gov/pubmed/28576561">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4571 href="https://doi.org/10.1016/j.ejps.2017.05.063">Publisher Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d20924e4580 class=n-a></a>Chang RYK, Chen K, Wang J, <i> et al.</i>: Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation. <i>Antimicrob Agents Chemother.</i> 2018; <b>62</b>(2): pii: e01714-17. <a target=xrefwindow id=d20924e4591 href="http://www.ncbi.nlm.nih.gov/pubmed/29158280">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4594 href="https://doi.org/10.1128/AAC.01714-17">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4598 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5786808">Free Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d20924e4607 class=n-a></a>Alvarado-Gomez E, Martínez-Castañon G, Sanchez-Sanchez R, <i> et al.</i>: Evaluation of anti-biofilm and cytotoxic effect of a gel formulation with Pluronic F-127 and silver nanoparticles as a potential treatment for skin wounds. <i>Mater Sci Eng C Mater Biol Appl.</i> 2018; <b>92</b>: 621–30. <a target=xrefwindow id=d20924e4618 href="http://www.ncbi.nlm.nih.gov/pubmed/30184789">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4621 href="https://doi.org/10.1016/j.msec.2018.07.023">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d20924e4630 class=n-a></a>Kłodzińska SN, Molchanova N, Franzyk H, <i> et al.</i>: Biopolymer nanogels improve antibacterial activity and safety profile of a novel lysine-based α-peptide/β-peptoid peptidomimetic. <i>Eur J Pharm Biopharm.</i> 2018; <b>128</b>: 1–9. <a target=xrefwindow id=d20924e4641 href="http://www.ncbi.nlm.nih.gov/pubmed/29605468">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4644 href="https://doi.org/10.1016/j.ejpb.2018.03.012">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d20924e4653 class=n-a></a>Anjum A, Sim CH, Ng SF: Hydrogels Containing Antibiofilm and Antimicrobial Agents Beneficial for Biofilm-Associated Wound Infection: Formulation Characterizations and <i>In vitro</i> Study. <i>AAPS PharmSciTech.</i> 2018; <b>19</b>(3): 1219–30. <a target=xrefwindow id=d20924e4664 href="http://www.ncbi.nlm.nih.gov/pubmed/29280044">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4667 href="https://doi.org/10.1208/s12249-017-0937-4">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d20924e4676 class=n-a></a>Gil J, Natesan S, Li J, <i> et al.</i>: A PEGylated fibrin hydrogel-based antimicrobial wound dressing controls infection without impeding wound healing. <i>Int Wound J.</i> 2017; <b>14</b>(6): 1248–57. <a target=xrefwindow id=d20924e4687 href="http://www.ncbi.nlm.nih.gov/pubmed/28771993">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4690 href="https://doi.org/10.1111/iwj.12791">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d20924e4700 class=n-a></a>Kalan LR, Pepin DM, Ul-Haq I, <i> et al.</i>: Targeting biofilms of multidrug-resistant bacteria with silver oxynitrate. <i>Int J Antimicrob Agents.</i> 2017; <b>49</b>(6): 719–26. <a target=xrefwindow id=d20924e4711 href="http://www.ncbi.nlm.nih.gov/pubmed/28390963">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4714 href="https://doi.org/10.1016/j.ijantimicag.2017.01.019">Publisher Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d20924e4723 class=n-a></a>Cryz SJ Jr, Lang A, Rüdeberg A, <i> et al.</i>: Immunization of cystic fibrosis patients with a <i>Pseudomonas aeruginosa</i> O-polysaccharide-toxin A conjugate vaccine. <i>Behring Inst Mitt.</i> 1997; (98): 345–9. <a target=xrefwindow id=d20924e4734 href="http://www.ncbi.nlm.nih.gov/pubmed/9382759">PubMed Abstract </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1089099"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e4743 class=n-a></a>Döring G, Meisner C, Stern M: A double-blind randomized placebo-controlled phase III study of a <i>Pseudomonas aeruginosa</i> flagella vaccine in cystic fibrosis patients. <i>Proc Natl Acad Sci U S A.</i> 2007; <b>104</b>(26): 11020–5. <a target=xrefwindow id=d20924e4754 href="http://www.ncbi.nlm.nih.gov/pubmed/17585011">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4757 href="https://doi.org/10.1073/pnas.0702403104">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4761 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1904125">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1089099">F1000 Recommendation</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d20924e4774 class=n-a></a>Baumann U, Mansouri E, von Specht BU: Recombinant OprF-OprI as a vaccine against <i>Pseudomonas aeruginosa</i> infections. <i>Vaccine.</i> 2004; <b>22</b>(7): 840–7. <a target=xrefwindow id=d20924e4785 href="http://www.ncbi.nlm.nih.gov/pubmed/15040936">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4788 href="https://doi.org/10.1016/j.vaccine.2003.11.029">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d20924e4797 class=n-a></a>Bumann D, Behre C, Behre K, <i> et al.</i>: Systemic, nasal and oral live vaccines against <i>Pseudomonas aeruginosa</i>: a clinical trial of immunogenicity in lower airways of human volunteers. <i>Vaccine.</i> 2010; <b>28</b>(3): 707–13. <a target=xrefwindow id=d20924e4811 href="http://www.ncbi.nlm.nih.gov/pubmed/19887136">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4815 href="https://doi.org/10.1016/j.vaccine.2009.10.080">Publisher Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727274395"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e4824 class=n-a></a>Rello J, Krenn CG, Locker G, <i> et al.</i>: A randomized placebo-controlled phase II study of a <i>Pseudomonas</i> vaccine in ventilated ICU patients. <i>Crit Care.</i> 2017; <b>21</b>: 22. <a target=xrefwindow id=d20924e4838 href="http://www.ncbi.nlm.nih.gov/pubmed/28159015">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4842 href="https://doi.org/10.1186/s13054-017-1601-9">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4845 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5291979">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727274395">F1000 Recommendation</a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d20924e4859 class=n-a></a>Aguilera-Herce J, García-Quintanilla M, Romero-Flores R, <i> et al.</i>: A Live Salmonella Vaccine Delivering PcrV through the Type III Secretion System Protects against <i>Pseudomonas aeruginosa</i>. <i>mSphere.</i> 2019; <b>4</b>(2): pii: e00116-19. <a target=xrefwindow id=d20924e4873 href="http://www.ncbi.nlm.nih.gov/pubmed/30996108">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4877 href="https://doi.org/10.1128/mSphere.00116-19">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4880 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6470209">Free Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d20924e4889 class=n-a></a>Cabral MP, García P, Beceiro A, <i> et al.</i>: Design of live attenuated bacterial vaccines based on D-glutamate auxotrophy. <i>Nat Commun.</i> 2017; <b>8</b>: 15480. <a target=xrefwindow id=d20924e4900 href="http://www.ncbi.nlm.nih.gov/pubmed/28548079">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4903 href="https://doi.org/10.1038/ncomms15480">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4907 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5458566">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d20924e4916 class=n-a></a>Elhosary MA, Bahey-El-Din M, AbdelBary A, <i> et al.</i>: Immunization with the ferric iron-binding periplasmic protein HitA provides protection against <i>Pseudomonas aeruginosa</i> in the murine infection model. <i>Microb Pathog.</i> 2019; <b>131</b>: 181–5. <a target=xrefwindow id=d20924e4930 href="http://www.ncbi.nlm.nih.gov/pubmed/30978430">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4934 href="https://doi.org/10.1016/j.micpath.2019.04.014">Publisher Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d20924e4943 class=n-a></a>Bianconi I, Alcalá-Franco B, Scarselli M, <i> et al.</i>: Genome-Based Approach Delivers Vaccine Candidates Against <i>Pseudomonas aeruginosa</i>. <i>Front Immunol.</i> 2019; <b>9</b>: 3021. <a target=xrefwindow id=d20924e4957 href="http://www.ncbi.nlm.nih.gov/pubmed/30687303">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4961 href="https://doi.org/10.3389/fimmu.2018.03021">Publisher Full Text </a> | <a target=xrefwindow id=d20924e4964 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6334337">Free Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d20924e4973 class=n-a></a>Naito Y, Hamaoka S, Kinoshita M, <i> et al.</i>: The protective effects of nasal PcrV-CpG oligonucleotide vaccination against <i>Pseudomonas aeruginosa</i> pneumonia. <i>Microbiol Immunol.</i> 2018; <b>62</b>(12): 774–85. <a target=xrefwindow id=d20924e4987 href="http://www.ncbi.nlm.nih.gov/pubmed/30378708">PubMed Abstract </a> | <a target=xrefwindow id=d20924e4991 href="https://doi.org/10.1111/1348-0421.12658">Publisher Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d20924e5000 class=n-a></a>Gholami M, Salimi Chirani A, Falak R, <i> et al.</i>: Induction of Specific Humoral Immune Response in Mice against a <i>Pseudomonas aeruginosa</i> Chimeric PilQ/PilA Protein. <i>Rep Biochem Mol Biol.</i> 2018; <b>7</b>(1): 38–44. <a target=xrefwindow id=d20924e5014 href="http://www.ncbi.nlm.nih.gov/pubmed/30324116">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5018 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6175586">Free Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d20924e5028 class=n-a></a>Kutateladze M, Adamia R: Bacteriophages as potential new therapeutics to replace or supplement antibiotics. <i>Trends Biotechnol.</i> 2010; <b>28</b>(12): 591–5. <a target=xrefwindow id=d20924e5036 href="http://www.ncbi.nlm.nih.gov/pubmed/20810181">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5039 href="https://doi.org/10.1016/j.tibtech.2010.08.001">Publisher Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736290759"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e5048 class=n-a></a>Kutateladze M, Adamia R: Phage therapy experience at the Eliava Institute. <i>Med Mal Infect.</i> 2008; <b>38</b>(8): 426–30. <a target=xrefwindow id=d20924e5056 href="http://www.ncbi.nlm.nih.gov/pubmed/18687542">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5059 href="https://doi.org/10.1016/j.medmal.2008.06.023">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736290759">F1000 Recommendation</a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d20924e5072 class=n-a></a>Villarroel J, Larsen M, Kilstrup M, <i> et al.</i>: Metagenomic Analysis of Therapeutic PYO Phage Cocktails from 1997 to 2014. <i>Viruses.</i> 2017; <b>9</b>(11): pii: E328. <a target=xrefwindow id=d20924e5083 href="http://www.ncbi.nlm.nih.gov/pubmed/29099783">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5086 href="https://doi.org/10.3390/v9110328">Publisher Full Text </a> | <a target=xrefwindow id=d20924e5090 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5707535">Free Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d20924e5099 class=n-a></a>Jennes S, Merabishvili M, Soentjens P, <i> et al.</i>: Use of bacteriophages in the treatment of colistin-only-sensitive <i>Pseudomonas aeruginosa</i> septicaemia in a patient with acute kidney injury-a case report. <i>Crit Care.</i> 2017; <b>21</b>(1): 129. <a target=xrefwindow id=d20924e5113 href="http://www.ncbi.nlm.nih.gov/pubmed/28583189">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5117 href="https://doi.org/10.1186/s13054-017-1709-y">Publisher Full Text </a> | <a target=xrefwindow id=d20924e5120 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5460490">Free Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d20924e5129 class=n-a></a>Furr CLL, Lehman SM, Morales SP, <i> et al.</i>: P084 Bacteriophage treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i> pneumonia in a cystic fibrosis patient. <i>J Cyst Fibros.</i> 2018; <b>17</b>(Supplement 3): S83. <a target=xrefwindow id=d20924e5143 href="https://doi.org/10.1016/S1569-1993(18)30381-3">Publisher Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734168781"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e5152 class=n-a></a>Jault P, Leclerc T, Jennes S, <i> et al.</i>: Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by <i>Pseudomonas aeruginosa</i> (PhagoBurn): A randomised, controlled, double-blind phase 1/2 trial. <i>Lancet Infect Dis.</i> 2019; <b>19</b>(1): 35–45. <a target=xrefwindow id=d20924e5166 href="http://www.ncbi.nlm.nih.gov/pubmed/30292481">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5170 href="https://doi.org/10.1016/S1473-3099(18)30482-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734168781">F1000 Recommendation</a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d20924e5184 class=n-a></a>Liu L, Liu B, Li Y, <i> et al.</i>: Successful control of resistance in <i>Pseudomonas aeruginosa</i> using antibiotic stewardship and infection control programs at a Chinese university hospital: a 6-year prospective study. <i>Infect Drug Resist.</i> 2018; <b>11</b>: 637–46. <a target=xrefwindow id=d20924e5198 href="http://www.ncbi.nlm.nih.gov/pubmed/29750044">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5202 href="https://doi.org/10.2147/IDR.S163853">Publisher Full Text </a> | <a target=xrefwindow id=d20924e5205 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5936004">Free Full Text </a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d20924e5214 class=n-a></a>Lewis RH, Sharpe JP, Swanson JM, <i> et al.</i>: Reinventing the wheel: Impact of prolonged antibiotic exposure on multidrug-resistant ventilator-associated pneumonia in trauma patients. <i>J Trauma Acute Care Surg.</i> 2018; <b>85</b>(2): 256–62. <a target=xrefwindow id=d20924e5225 href="http://www.ncbi.nlm.nih.gov/pubmed/29664891">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5228 href="https://doi.org/10.1097/TA.0000000000001936">Publisher Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d20924e5237 class=n-a></a>Döring G: Prevention of <i>Pseudomonas aeruginosa</i> infection in cystic fibrosis patients. <i>Int J Med Microbiol.</i> 2010; <b>300</b>(8): 573–7. <a target=xrefwindow id=d20924e5248 href="http://www.ncbi.nlm.nih.gov/pubmed/20940108">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5251 href="https://doi.org/10.1016/j.ijmm.2010.08.010">Publisher Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d20924e5260 class=n-a></a>Garvey MI, Bradley CW, Holden E: Waterborne <i>Pseudomonas aeruginosa</i> transmission in a hematology unit? <i>Am J Infect Control.</i> 2018; <b>46</b>(4): 383–6. <a target=xrefwindow id=d20924e5271 href="http://www.ncbi.nlm.nih.gov/pubmed/29195780">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5274 href="https://doi.org/10.1016/j.ajic.2017.10.013">Publisher Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d20924e5283 class=n-a></a>Kumarage J, Khonyongwa K, Khan A, <i> et al.</i>: Transmission of multi-drug resistant <i>Pseudomonas aeruginosa</i> between two flexible ureteroscopes and an outbreak of urinary tract infection: the fragility of endoscope decontamination. <i>J Hosp Infect.</i> 2019; <b>102</b>(1): 89–94. <a target=xrefwindow id=d20924e5297 href="http://www.ncbi.nlm.nih.gov/pubmed/30802523">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5301 href="https://doi.org/10.1016/j.jhin.2019.02.015">Publisher Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d20924e5310 class=n-a></a>Wiehlmann L, Cramer N, Ulrich J, <i> et al.</i>: Effective prevention of <i>Pseudomonas aeruginosa</i> cross-infection at a cystic fibrosis centre - results of a 10-year prospective study. <i>Int J Med Microbiol.</i> 2012; <b>302</b>(2): 69–77. <a target=xrefwindow id=d20924e5324 href="http://www.ncbi.nlm.nih.gov/pubmed/22196973">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5328 href="https://doi.org/10.1016/j.ijmm.2011.11.001">Publisher Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d20924e5338 class=n-a></a>Cramer N, Wiehlmann L, Tümmler B: Clonal epidemiology of <i>Pseudomonas aeruginosa</i> in cystic fibrosis. <i>Int J Med Microbiol.</i> 2010; <b>300</b>(8): 526–33. <a target=xrefwindow id=d20924e5349 href="http://www.ncbi.nlm.nih.gov/pubmed/20951087">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5352 href="https://doi.org/10.1016/j.ijmm.2010.08.004">Publisher Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d20924e5361 class=n-a></a>Saiman L, Siegel JD, LiPuma JJ, <i> et al.</i>: Infection prevention and control guideline for cystic fibrosis: 2013 update. <i>Infect Control Hosp Epidemiol.</i> 2014; <b>35 Suppl 1</b>: S1–S67. <a target=xrefwindow id=d20924e5372 href="http://www.ncbi.nlm.nih.gov/pubmed/25025126">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5375 href="https://doi.org/10.1086/676882">Publisher Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733253161"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e5384 class=n-a></a>Robak OH, Heimesaat MM, Kruglov AA, <i> et al.</i>: Antibiotic treatment-induced secondary IgA deficiency enhances susceptibility to <i>Pseudomonas aeruginosa</i> pneumonia. <i>J Clin Invest.</i> 2018; <b>128</b>(8): 3535–45. <a target=xrefwindow id=d20924e5398 href="http://www.ncbi.nlm.nih.gov/pubmed/29771684">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5402 href="https://doi.org/10.1172/JCI97065">Publisher Full Text </a> | <a target=xrefwindow id=d20924e5405 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6063483">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733253161">F1000 Recommendation</a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734570161"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e5418 class=n-a></a>Ackermann M, Kempf H, Hetzel M, <i> et al.</i>: Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections. <i>Nat Commun.</i> 2018; <b>9</b>(1): 5088. <a target=xrefwindow id=d20924e5429 href="http://www.ncbi.nlm.nih.gov/pubmed/30504915">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5432 href="https://doi.org/10.1038/s41467-018-07570-7">Publisher Full Text </a> | <a target=xrefwindow id=d20924e5436 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6269475">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734570161">F1000 Recommendation</a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d20924e5449 class=n-a></a>Rasmussen TB, Bjarnsholt T, Skindersoe ME, <i> et al.</i>: Screening for quorum-sensing inhibitors (QSI) by use of a novel genetic system, the QSI selector. <i>J Bacteriol.</i> 2005; <b>187</b>(5): 1799–814. <a target=xrefwindow id=d20924e5460 href="http://www.ncbi.nlm.nih.gov/pubmed/15716452">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5463 href="https://doi.org/10.1128/JB.187.5.1799-1814.2005">Publisher Full Text </a> | <a target=xrefwindow id=d20924e5467 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1063990">Free Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d20924e5476 class=n-a></a>García-Contreras R, Pérez-Eretza B, Lira-Silva E, <i> et al.</i>: Gallium induces the production of virulence factors in <i>Pseudomonas aeruginosa</i>. <i>Pathog Dis.</i> 2014; <b>70</b>(1): 95–8. <a target=xrefwindow id=d20924e5490 href="http://www.ncbi.nlm.nih.gov/pubmed/24151196">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5494 href="https://doi.org/10.1111/2049-632X.12105">Publisher Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735713406"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20924e5504 class=n-a></a>Dedrick RM, Guerrero-Bustamante CA, Garlena RA, <i> et al.</i>: Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant <i>Mycobacterium abscessus</i>. <i>Nat Med.</i> 2019; <b>25</b>(5): 730–3. <a target=xrefwindow id=d20924e5518 href="http://www.ncbi.nlm.nih.gov/pubmed/31068712">PubMed Abstract </a> | <a target=xrefwindow id=d20924e5522 href="https://doi.org/10.1038/s41591-019-0437-z">Publisher Full Text </a> | <a target=xrefwindow id=d20924e5525 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6557439">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735713406">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Aug 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1371/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1371/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Clinical Research Group &lsquo;Molecular Pathology of Cystic Fibrosis&rsquo; and &lsquo;Pseudomonas Genomics&rsquo;, Clinic for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, 30625, Germany<br/> <sup>2</sup> Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), German Center of Lung Disease, Hannover, 30625, Germany<br/> <sup>3</sup> Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, 30625, Germany<br/> <p> <div class=margin-bottom> Burkhard T&uuml;mmler <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1371/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 07 Aug 2019, 8:1371 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.19509.1">https://doi.org/10.12688/f1000research.19509.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Tümmler B. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=21389 data-id=19509 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19509.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1371/v1/pdf?article_uuid=0eff2244-23d3-4064-8840-1f3d64839ba8" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.19509.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Tümmler B. Emerging therapies against infections with <i>Pseudomonas aeruginosa</i> [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1371 (<a href="https://doi.org/10.12688/f1000research.19509.1" target=_blank>https://doi.org/10.12688/f1000research.19509.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=19509 id=mobile-track-article-signin-19509 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19509?target=/articles/8-1371/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21389 /> <input name=articleId type=hidden value=19509 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Jos&eacute; Luis Mart&iacute;nez</strong>, Department of Microbial Biotechnology, CNB - Spanish National Centre for Biotechnology, Spain </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Antonio Oliver</strong>, Servicio de Microbiología Módulo J, segundo piso, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Spain </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Aug 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1371/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1371/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=53298-52186></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=53299-52187></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1371/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>07 Aug 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jos&eacute; Luis Mart&iacute;nez</strong>, Department of Microbial Biotechnology, CNB - Spanish National Centre for Biotechnology, Spain </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Antonio Oliver</strong>, Servicio de Microbiología Módulo J, segundo piso, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Spain </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1371/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1371/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Emerging therapies against infections with...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1371/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1371/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1371/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Tümmler B');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1371/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1371",
            templates : {
                twitter : "Emerging therapies against infections with Pseudomonas aeruginosa. Tümmler B, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1371/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Emerging therapies against infections with Pseudomonas aeruginosa", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Emerging therapies against infections with Pseudomonas aeruginosa", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/19509/21389")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "21389");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "52186": 0,
                           "52187": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "37053ad2-369d-44c9-8a25-be14ef69fa9f";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1371.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1371.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1371.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1371.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1371.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>